



(11) **EP 3 752 839 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**20.11.2024 Bulletin 2024/47**

(21) Application number: **19710820.2**

(22) Date of filing: **07.02.2019**

(51) International Patent Classification (IPC):  
**G01N 33/68** <sup>(2006.01)</sup> **G01N 1/28** <sup>(2006.01)</sup>  
**G01N 1/30** <sup>(2006.01)</sup> **B01L 3/00** <sup>(2006.01)</sup>  
**G01N 33/483** <sup>(2006.01)</sup> **B01J 19/00** <sup>(2006.01)</sup>  
**G01N 1/34** <sup>(2006.01)</sup> **H01J 49/04** <sup>(2006.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**G01N 1/2813; A61B 10/02; B01J 19/0046;**  
**B01L 3/50853; B01L 3/5088; C12Q 1/6881;**  
**C40B 60/04; G01N 1/30; G01N 1/312; G01N 1/34;**  
**G01N 33/4833; G01N 33/68; G01N 33/6848;**  
**G02B 21/32; B01J 2219/00317;** (Cont.)

(86) International application number:  
**PCT/US2019/017009**

(87) International publication number:  
**WO 2019/160739 (22.08.2019 Gazette 2019/34)**

(54) **NANOSCALE BIOCHEMICAL SAMPLE PREPARATION AND ANALYSIS**

NANOSKALIGE BIOCHEMISCHE PROBENVORBEREITUNG UND -ANALYSE

ANALYSE ET PRÉPARATION D'ÉCHANTILLONS BIOCHIMIQUES DE TAILLE NANOMÉTRIQUE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **14.02.2018 US 201815897022**

(43) Date of publication of application:  
**23.12.2020 Bulletin 2020/52**

(73) Proprietor: **Battelle Memorial Institute**  
**Richland, Washington 99354 (US)**

(72) Inventors:  
• **KELLY, Ryan, T.**  
**Richland, WA 99352 (US)**  
• **ZHU, Ying**  
**Richland, WA 99352 (US)**  
• **SMITH, Richard, D.**  
**Richland, WA 99352 (US)**

(74) Representative: **HGF**  
**HGF Limited**  
**1 City Walk**  
**Leeds LS11 9DX (GB)**

(56) References cited:  
**WO-A1-2017/144886 WO-A1-2017/205687**  
**DE-A1- 102004 041 941 US-A1- 2010 261 159**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 752 839 B1**

(52) Cooperative Patent Classification (CPC): (Cont.)

B01J 2219/00367; B01J 2219/00619;  
B01J 2219/00621; B01J 2219/00659;  
B01J 2219/00702; B01J 2219/00725;  
B01J 2219/00743; B01L 2200/142;  
B01L 2300/0819; B01L 2300/0822;  
B01L 2300/0887; G01N 2001/284

**Description**

## STATEMENT UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

5 **[0001]** This invention was made with Government support under grant no. R21EB020976 and P41GM103493 awarded by the National Institutes of Health and contract number DE-AC05-76RL01830 awarded by the Department of Energy. The government has certain rights in the invention.

## FIELD

10

**[0002]** Embodiments of the disclosure generally relate to methods for biochemical analysis.

## BACKGROUND

15 **[0003]** Human tissues are often highly heterogeneous, consisting of intermixed cellular populations and morphological substructures. Mass spectrometry (MS)-based proteomic analyses can require samples comprising thousands to millions of cells to provide an in-depth profile of protein expression, which can severely limit the ability to analyze small samples and resolve microheterogeneity within tissues. While MS sensitivity has steadily improved, the inability to effectively prepare and deliver such trace samples to the analytical platform has proven limiting.

20 **[0004]** Document WO2017144886 A1 discloses a method for preparing a biological sample, comprising the steps of: obtaining a biological tissue sample via tissue laser-capture microdissection;

25 providing a platform including at least one reactor vessel having one or more hydrophilic surfaces configured for containment of the biological tissue sample, wherein the hydrophilic surfaces have a non-zero, total surface area less than 25 mm<sup>2</sup>;

introducing a capture liquid into or onto the at least one reactor vessel;

transferring a first volume of the biological tissue sample to the at least one reactor vessel that includes the capture liquid, wherein the first volume is a non-zero amount less than 1000 nL; subsequently

processing the biological tissue sample in the at least one reactor vessel to yield a processed sample.

30

**[0005]** Accordingly, improved methods are needed for proteomic analysis using small sample sizes.

## SUMMARY

35 **[0006]** Provided herein, *inter alia*, are compositions and methods for processing and analysis of small cell populations and biological samples (e.g., a robotically controlled chip-based nanodroplet platform). In particular aspects, the methods described herein can reduce total processing volumes from conventional volumes to nanoliter volumes within a single reactor vessel (e.g., within a single droplet reactor) while minimizing losses, such as due to sample evaporation.

40 **[0007]** Embodiments described herein can provide advantages over existing methods, which can require samples including a minimum of thousands of cells to provide in-depth proteome profiling. As described herein, embodiments of the disclosure can dramatically enhance the efficiency and recovery of sample processing through downscaling total processing volumes to the nanoliter range, while substantially avoiding sample loss.

**[0008]** The present invention provides a method according to claim 1. Preferred embodiments are provided in the dependent claims.

45 **[0009]** Described herein are methods for preparing a biological sample, comprising obtaining a biological sample, and providing a platform. The platform includes at least one reactor vessel having one or more hydrophilic surfaces configured for containment of the biological sample, wherein the hydrophilic surfaces have a non-zero, total surface area less than 25 mm<sup>2</sup>. In other embodiments, the hydrophilic surfaces of the at least one reactor vessel have a total surface area of less than 1 mm<sup>2</sup>.

50 **[0010]** The method includes transferring a first volume (a non-zero amount less than 1000 nL) of the biological sample to a single reactor vessel. Furthermore the methods include processing the biological sample in the single reactor vessel to yield a processed sample, and collecting a second volume of the processed sample (e.g., the second volume is a fraction of the first volume ranging from about 10 to about 100 %).

55 **[0011]** The biological sample include tissues and can include at least one of biopsies, cell homogenates, cell fractions, cultured cells, non-cultured cells, whole blood, plasma, and biological fluids. In embodiments, the biological sample is less than 1000 nL. In other embodiments, the biological sample is less than 100 nL.

**[0012]** In various aspects, the methods of obtaining the biological sample may include, for example, dispensing cellular material from suspension and fluorescence-activated cell sorting.

**[0013]** In further aspects, the method may further comprise at least two reactor vessels, wherein the at least two reactor vessels are separated by a hydrophobic surface.

**[0014]** In embodiments, the biological sample for the methods described herein may include a non-zero amount of cells less than 5000 cells, less than 100 cells or less than 10 cells.

**[0015]** In other embodiments, the methods described herein further include analyzing the collected second volume (e.g., the second volume is a fraction of the first volume ranging from about 10 to about 100 %) of the processed biological sample, and the analyzing step is configured to identify at least one unique species within the processed biological sample. In other embodiments, the analyzing step identifies at least 1,000 unique species, at least 3,000 unique species, or at least 5,000 unique species. In various embodiments, analyzing can identify greater than 3,000 unique species from 10 or less cells.

**[0016]** In embodiments, the unique species may include at least one of proteins or fragments thereof, lipids, or metabolites.

**[0017]** In other embodiments, the methods described herein further include analyzing the collected second volume, and wherein the analyzing step comprises mass spectrometry or flow cytometry.

**[0018]** In aspects, the platform of the methods described herein includes a glass chip. In other aspects, the glass chip is pre-coated, e.g., with chromium, aluminum, or gold. In other aspects, the glass chip includes a substrate containing the at least one reactor vessel, a spacer containing an aperture positioned on the substrate, and a cover positioned on the spacer, wherein the aperture is dimensioned to surround the at least one reactor vessel when the spacer is positioned on the substrate. In other aspects, the steps involving dispensing and aspiration of sample and processing reagents are performed in a humidity-controlled chamber (e.g., which is maintained from about 80% to about 95%).

**[0019]** The methods described herein include processing the biological sample. Processing the biological sample may include at least one of cell lysis, analyte extraction and solubilization, denaturation, reduction, alkylation, chemical and enzymatic reactions, concentration, and incubation.

**[0020]** In aspects, the methods described herein include collecting the processed sample into a capillary. In other aspects, collecting the processed sample into a capillary includes aspirating the processed sample into the capillary and washing the single reactor vessel with a solvent. Additionally, the capillary may be sealed from the external environment after the processed sample is collected therein. The methods described herein include biological samples comprising of tissues. The tissue includes laser-capture microdissected tissues, e.g., having dimensions less than about 1 mm.

**[0021]** Each of the aspects and embodiments described herein are capable of being used together, unless excluded either explicitly or clearly from the context of the embodiment or aspect.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0022]** These and other features will be more readily understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

**FIG. 1** is a schematic depicting an exemplary operating environment including a robotic platform configured to dispense biological samples and reagents into a chip containing one or more reactor vessels (e.g., nanovessel) for nanoscale sample preparation.

**FIG. 2** is a schematic of the chip of FIG. 1 including a substrate, a spacer, a sealing membrane, and a cover slide. The cover slide can be reversibly secured to the spacer for dispensing and incubation

**FIGS. 3A-3E** are schematics depicting examples of procedures for fabrication and surface modification of a substrate of the chip of FIG. 2. **FIG. 3A** depicts a schematic of the fabrication and assembly of the chip, where the chip may be pre-coated with an anti-reflective coating (e.g., chromium) and photoresist. **FIG. 3B** depicts a chip after etching the photomask. **FIG. 3C** depicts the chip after etching the anti-reflective coating and the substrate to form a patterned substrate. **FIG. 3D** depicts the patterned substrate including the anti-reflective coating after removal of the photoresist. **FIG. 3E** depicts the chip after removal of the anti-reflective coating, showing a pattern of pillars and wells.

**FIGS. 4A-4B** are diagrams illustrating exemplary reactor vessels defined by the chip patterned substrate of the chip including pillars and wells formed there between. **FIG. 4A** depicts one exemplary patterned substrate where the one or more reactor vessels is defined by the upper surfaces of the pillars. The pillars can include hydrophilic upper surfaces and the wells can include hydrophobic upper surfaces. **FIG. 4B** depicts another exemplary patterned substrate where the one or more reactor vessels is defined by the wells, between the pillars. In each of FIGS. 4A-4B, the hydrophilic surfaces can be provided by the bare surface of the substrate (e.g., glass surfaces) or hydrophilic coatings. The hydrophobic surfaces can be provided by hydrophobic coatings.

**FIG. 5** depicts another exemplary patterned chip substrate in a substantially planar configuration, where the reactor vessels are flush with the substrate surface and defined within first regions of the substrate having hydrophilic surfaces and bounded by adjacent second regions having hydrophobic surfaces.

**FIG. 6** depicts a flow diagram illustrating one exemplary embodiment of a sample preparation protocol for the methods described herein including a biological sample treatment operation.

**FIGS. 7-8** depict schematics of exemplary sample preparation of the methods described herein. **FIG. 7** depicts exemplary workflow of a sample, including, extraction/reduction, alkylation, Lys-C digestion, trypsin digestion, surfactant cleavage and peptide collection. **FIG. 8** depicts an exemplary workflow of a sample (e.g., cells) that are lysed, alkylated, digested - by Lys C and trypsin.

**FIG. 9** illustrates an exemplary operating environment including a transfer vessel in the form of a capillary collecting a processed biological sample via aspiration from the nanowell chip.

**FIG. 10** is a schematic of a capillary used to collect processed sample which can be readily connected to an analytical instrument, such as a mass spectrometer.

**FIGS. 11A-11C** depict preliminary proteomic results employing the sample preparation method of **FIG. 6**. **FIG. 11A** depicts a base peak chromatogram acquired from 160 cells; an embodiment of a nanowell with cells positioned therein is shown in the insert. **FIG. 11B** is a bar graph depicting peptide spectral matches (PSMs), unique peptides and identified proteins from duplicate runs of the 160 cells. **FIG. 11C** depicts a schematic showing the protein overlap from duplicate runs.

**FIGS. 12A-12C** are images depicting HeLa cells in nanowells. **FIG. 12A** depicts 12 HeLa cells. **FIG. 12B** depicts 42 HeLa cells. **FIG. 12C** depicts 139 HeLa cells.

**FIGS. 13A-13C** are base chromatograms of the HeLa cells in nanowells corresponding to **FIGS. 12A-12C**, respectively.

**FIGS. 14A-14B** show the sensitivity and reproducibility of the nanoPOTS platform. **FIGS. 14A-14B** are bar graphs depicting the number of unique peptides (**FIG. 14A**) and protein groups identified from different cell loadings (**FIG. 14B**).

**FIG. 15** presents bar graphs depicting peptide and protein identification from three blank control samples including solid phase extraction (SPE) and liquid chromatography (LC) columns, sample preparation reagents, and cell supernatant. To evaluate cross contamination from SPE and LC column, buffer A (e.g., storage buffer) was directly injected into SPE for LC-MS. To evaluate cross contamination from sample preparation reagents, PBS buffer instead of cells was dispensed into nanowells, followed by all proteomic processing steps, e.g., from **FIGS. 5-7**. To evaluate cross contamination from cell supernatant, cell suspension with a concentration of ~200 cell/ $\mu$ L was centrifuged at 2000 rpm for 10 min. The supernatant was dispensed into nanowells followed by all proteomic processing steps. All identification experiments were run after ~100-cell samples.

**FIGS. 16A-16B** are graphs depicting the distribution of copy number per cell for proteins identified from 10-14 HeLa cells by matching with previously-reported databases, containing 40 proteins obtained with PreEST-SILAC method (Tyanova et al.) (**FIG. 16A**), and 5443 proteins using the histone-based "proteomic ruler" method (**FIG. 16B**).

**FIGS. 17A-17D** are images depicting the label-free quantification (LFQ) reproducibility. Pairwise correlation of protein LFQ intensities, between, 10-cell and 12-cell samples (**FIG. 17A**), 37-cell and 42-cell samples (**FIG. 17B**), 137-cell and 141-cell samples (**FIG. 17C**). The densities correspond to the greyscale code in **FIG. 17A**. **FIG. 17D** depicts a violin plot showing the distributions of coefficients of variance of protein LFQ intensities for the three cell loading groups (10-12 cells, 37-41 cells, and 137-141 cells).

**FIGS. 18A-18D** depict box charts showing the distributions of (a1 **FIG. 18A**, b1 **FIG. 18B**) coefficients of variance and (a2 **FIG. 18C**, b2 **FIG. 18D**) log intensities at (a1, a2) peptide and (b1, b2) protein level for three cell loading groups. Peptide intensities were normalized based on global normalization approach in each cell loading group. LFQ intensities generated by Maxquant were used for protein quantification.

**FIG. 19** depicts a schematic showing the workflow of the isolation of laser microdissected of human pancreatic islets into nanowells.

**FIG. 20A** depicts images showing the pairwise correlation analysis of protein expression level in nine human islet slices.

**FIG. 20B** depicts images of the nine islet sections used as described herein.

**FIG. 21** depicts an image showing the protein coverage of a network involved in vesicular transport.

**FIG. 22** depicts a bar graph depicting the evaluation of trypsin digestion efficiency. Percentages of full tryptic peptides and peptides with missed-cleavage sites for samples with cell numbers from 10 to 141.

**FIGS. 23A-23D** depicts images of (a-b) overlap of identified protein groups from three cell loading groups with **(FIG. 23A)** MS/MS only method, and **(FIG. 23B)** combined MS/MS and MBR method. **(FIG. 23C-23D)** Overlap of protein groups identified from similar cell loadings of 10, 12, and 14 cells with **(FIG. 23C)** MS/MS only method, and **(FIG. 23D)** combined MS/MS and MBR method.

**FIGS. 24A-24C** are bar graphs depicting the quantifiable numbers of **(FIG. 24A)** peptide numbers and **(FIG. 24B and FIG. 24C)** protein group numbers for three cell loading groups. Peptides and proteins having intensities in all 3 samples with similar cell numbers were counted as quantifiable identifications.

**FIGS. 25A-25C** depicts a pairwise correlation analysis of any two samples in peptide intensity level with cell loadings groups of **(FIG. 25A)** 10-14 cells, **(FIG. 25B)** 37-45 cells, and **(FIG. 25C)** 137-141 cells.

**FIGS. 26A-26C** depicts a pairwise correlation analysis of any two samples in protein intensity level with cell loadings groups of **(FIG. 26A)** 10-14 cells, **(FIG. 26B)** 37-45 cells, and **(FIG. 26C)** 137-141 cells. LFQ intensity generated from Maxquant was used for protein intensity calculation.

**FIG. 27** is a bar graph depicting the comparison of Gene Ontology annotations for Cellular Component showing the protein identified from nanoPOTS and SNaPP platforms (Sun, L. et al.). In nanoPOTS platform, datasets were generated 9 slices of LCM islets. In SNaPP platform, datasets were generated from triplicate runs of more than 100 islets.

**FIG. 28** depicts a graph showing the number of proteins identified versus the number of mammalian cells for previously published platforms (blue) and the present platform (red), indicating that the present platform has achieved greater proteome coverage from just 10-14 cells than was achieved previously from much larger samples.

**FIGS. 29A-29E (FIG. 29A)** Schematic diagram showing the direct integration of laser capture microdissection (LCM) with a nanowell chip using dimethyl sulfoxide (DMSO) droplets for tissue capture. **(FIG. 29B)** Image of a nanowell chip with an array of 200-nL pre-populated DMSO droplets. **(FIG. 29C)** Direct mounting of a nanowell chip on a slide adapter for a PALM microbeam LCM system. **(FIG. 29D)** Microdissected tissue section and **(FIG. 29E)** the corresponding tissue pieces collected in nanowells with square side lengths from 20  $\mu\text{m}$  to 200  $\mu\text{m}$ . A 12- $\mu\text{m}$ -thick breast cancer tissue was used as a model sample.

**FIGS. 30A-30B (FIG. 30A)** Comparison of evaporation time of water and DMSO droplets with different volumes. Each condition was measured with five replicates. **(FIG. 30B)** Evaluation of the capture efficiency of LCM tissue samples using DMSO droplets. A breast tissue section (12  $\mu\text{m}$  thick) was used as a model sample. The replicates were 75, 75, 75, and 27 for the tissues having side lengths of 20  $\mu\text{m}$ , 50  $\mu\text{m}$ , 100  $\mu\text{m}$ , and 200  $\mu\text{m}$ , respectively. 200 nL DMSO droplets predeposited in nanowells with a diameter of 1.2 mm were used for tissue collection.

**FIGS. 31A-31G** Unique peptides **(FIG. 31A)** and protein identifications **(FIG. 31B)** of rat brain cortex tissue samples obtained with laser capture microdissection followed by DMSO and DMSO-free-based sample collection methods. **(FIG. 31C)** Venn diagram of the total protein identifications. Tissue size: 200  $\mu\text{m}$  in diameter and 12  $\mu\text{m}$  in depth. **(FIGS. 31D-31F)** Evaluation of the sensitivity of the LCM-DMSO-nanoPOTS system in proteomic analysis of small rat cortex tissue samples. The relationship of tissue sizes with unique peptides **(FIG. 31D)** and protein **(FIG. 31E)** identifications, and **(FIG. 31F)** the overlap of total protein identifications in different sizes. **(FIG. 31G)** GOCC analysis of the 1918 proteins identified from 200- $\mu\text{m}$  cortex tissues using an online tool DAVID. All peptide and protein

identifications were based on MS/MS spectra (Match Between Runs was disabled). Each condition was analyzed in triplicate.

**FIGS. 32A-32C. (FIG. 32A)** The rat brain coronal section (12  $\mu\text{m}$  thick) used in the study. Three distinct regions including cerebral cortex (CTX), corpus callosum (CC), and caudoputamen (CP) were dissected with a spatial resolution of 100  $\mu\text{m}$  in diameter. **(FIG. 32B)** The corresponding microscopic images of the tissue regions after dissection. **(FIG. 32C)** Pair wise correlation plots with  $\log_2$ -transformed LFQ intensities between total 12 tissue samples from the three regions. The color codes indicate the relatively high correlations between the same tissue regions and relatively low correlations between different regions.

**FIGS. 33A-33B. (FIG. 33A)** Principle component analysis (PCA) of protein expressions in CTX, CC, and CP regions of rat brain section as shown in **FIGS. 32A-32C. (FIG. 33B)** Hierarchical clustering analysis (HCA) of the significant proteins.

**FIG. 34A** depicts a top front view of a chip showing droplets hanging from the individual reactor vessels during incubation.

**FIG. 34B** depicts a side view of a chip showing droplets hanging from the individual reactor vessels during incubation.

**[0023]** It is noted that the drawings are not necessarily to scale. The drawings are intended to depict only typical aspects of the subject matter disclosed herein, and therefore should not be considered as limiting the scope of the disclosure. Those skilled in the art will understand that the systems, devices, and methods specifically described herein and illustrated in the accompanying drawings are non-limiting exemplary embodiments and that the scope of the disclosed embodiments is defined solely by the claims.

#### DETAILED DESCRIPTION

**[0024]** Embodiments of the present disclosure relate to methods for preparation and analytical analysis of biological samples. More particularly, embodiments of the present disclosure relate to preparation and analysis of biological samples having nanoscale volumes, interchangeably referred to herein as nanoPOTS: Nanowell-based Preparation in One-pot for Trace Samples. As discussed in detail below, increased efficiency and recovery of proteomic sample processing by downscaling total preparation volumes to the nanoliter range (e.g., from the range of about 100  $\mu\text{L}$  to about less than 5  $\mu\text{L}$ ).

**[0025]** Described herein, proteomic sample preparation and analysis for small cell populations can be improved, for example by reducing the total processing volume to the nanoliter range within a single reactor vessel. The present platform, NanoPOTS, can enable each sample to be processed within a 200 nL or smaller droplet that is contained in a wall-less glass reactor having a diameter of approximately 1 mm (e.g., total surface area of about 0.8  $\text{mm}^2$ ). Compared with a 100  $\mu\text{L}$  typical sample preparation volume in 0.5 mL-centrifuge tubes (127.4  $\text{mm}^2$ ), the surface area was reduced by a factor of  $\sim 160$ , greatly reducing adsorptive losses.

**[0026]** When combined with analysis by ultrasensitive liquid chromatography-mass spectroscopy (LC-MS), biological samples prepared using nanoPOTS can enable deep profiling of greater than about 3000 proteins from as few as about 10 HeLa cells, a level of proteome coverage that has not been previously achieved for fewer than 10,000 mammalian cells. Beneficially, NanoPOTS can enable robust, quantitative and reproducible analyses and provide in-depth characterization of tissue substructures by profiling thin sections of single human islets isolated from clinical pancreatic specimens.

#### Current State of Molecular Profiling

**[0027]** One of the most dramatic technological advances in biological research has been the development of broad "omics-based" molecular profiling capabilities and their scaling to much smaller sample sizes than were previously feasible, including single cells. Highly sensitive genome amplification and sequencing techniques have been developed for the analysis of rare cell populations, interrogation of specific cells and substructures of interest within heterogeneous clinical tissues, and profiling of fine needle aspiration biopsies (Achim, K. et al., Jaitin, D. et al., and Shapiro E. et al). However, genomic and transcriptomic technologies can fail to comprehensively inform on cellular state (e.g., phenotype) (Bendall, S. et al.). Broad proteome measurements provide more direct characterization of the phenotypes and are crucial for understanding cellular functions and regulatory networks. Flow cytometry (FC) and mass cytometry (MC) (Smith, R. et al.) approaches can utilize antibody-bound reporter species to enable the detection of up to tens of surface markers and intracellular proteins from single cells. As with other antibody-based technologies, these methods can be fully dependent on the availability, quality and delivery of functional antibody probes. FC and MC are also inherently

targeted techniques with limited multiplexing capacity. Mass spectrometry (MS)-based proteomics is capable of broadly revealing protein expression as well as protein post-translational modifications (PTMs) within complex samples, but thousands to millions of cells are typically required to achieve deep proteome coverage.

**[0028]** In the absence of methods for global protein amplification, considerable efforts have been devoted to enhancing the overall analytical sensitivity of MS-based proteomics.<sup>6</sup> For example, liquid-phase separations including liquid chromatography (LC) and capillary electrophoresis (CE) have been miniaturized to reduce the total flow rate, leading to enhanced efficiencies at the electrospray ionization (ESI) source (Sun, L. et al., and Kelly, R. et al.). Advanced ion focusing approaches and optics such as the electrodynamic ion funnel (Li, S. et al) can minimize ion losses in the transfer from the atmospheric pressure ESI source to the high-vacuum mass analyzer, and are now incorporated into many biological MS platforms. As a result of these and other improvements, mass detection limits as low as 10 zmol for MS and 50 zmol for tandem MS analysis of peptides can be achieved (Shen, Y. et al., Sun, L. et al. Kelly, R. et al, Sun, X. et al. and Wang, H. et al). This analytical sensitivity can be sufficient to detect many proteins at levels expressed in single mammalian cells (Sun, L. et al. and Kelly, R. et al). However, despite this capability, such performance for 'real' application to such small samples remains largely ineffective.

**[0029]** The major gap between demonstrated single-cell analytical sensitivity and the present practical need for orders of magnitude more starting material largely can derive from limitations in required sample preparation, including sample isolation, cell lysis, protein extraction, proteolytic digestion, cleanup and delivery to the analytical platform. As sample sizes decrease without a concomitant reduction in reaction volume (often limited by evaporation and the ~microliter volumes addressable by pipet), the nonspecific adsorption of proteins and peptides to the surfaces of reactor vessels, along with inefficient digestion kinetics, can become increasingly problematic.

**[0030]** Efforts to improve sample preparation procedures include the use of low-binding sample tubes and 'one pot' digestion protocols to limit total surface exposure (Sun, X. et al., Wisniewski, J. et al, Chen, Q. et al, Chen W. et al, Waanders, L. et al, Huang, E. et al, and Wang, N. et al). In addition, trifluoroethanol-based protein extraction and denaturation (Wisniewski, J. et al 2011), filter-aided sample preparation,<sup>13</sup> MS-friendly surfactants (Waanders, L. et al, and Huang E., et al), high-temperature trypsin digestion (Chen, W. et al), adaptive focused acoustic-assisted protein extraction (Sun, X. et al), and immobilized digestion protocols (Wisniewski, J. et al 2011) have further advanced processing of small samples. Using methods such as these, previous work has shown that ~600 to 1500 proteins can be identified from samples comprising 100 to 2000 cells (Table 1 below) (Sun, X. et al, Chen, Q. et al, Chen, W. et al, Waanders, L. et al, Huang, E. et al. and Wang, N. et al).

**[0031]** Recently, single-cell proteomics has been used to explore protein expression heterogeneity in individual blastomeres isolated from *Xenopus laevis* embryos (Lombard-Banek, C. et al, and Sun, L. et al). These measurements were enabled by the fact each of these large cells contained micrograms of proteins, compared to the ~0.1 ng (Wisniewski, J. et al. 2014) of protein found in typical mammalian cells, and were thus compatible with conventional sample preparation protocols.

**[0032]** While progress has been made in enabling the proteomic analysis of trace samples, it is clear that further reducing sample requirements to biological samples containing low- or subnanogram amounts of protein while maintaining or increasing proteome coverage can enable many new applications.

### Samples

**[0033]** Samples may be any liquid, semi-solid or solid substance (or material). A sample can be a biological sample or a sample obtained from a biological material. A biological sample can be any solid or fluid sample obtained from, excreted by or secreted by any living organism, including without limitation, single celled organisms, such as bacteria, yeast, protozoans, and amoebas among others, multicellular organisms (such as plants or animals, including samples from a healthy or apparently healthy human subject or a human patient affected by a condition or disease to be diagnosed or investigated, such as cancer). For example, a biological sample can be a biological fluid obtained from, for example, blood, plasma, serum, urine, bile, ascites, saliva, cerebrospinal fluid, aqueous or vitreous humor, or any bodily secretion, a transudate, an exudate (for example, fluid obtained from an abscess or any other site of infection or inflammation), or fluid obtained from a joint (for example, a normal joint or a joint affected by disease).

**[0034]** A biological sample can also be a sample obtained from any organ or tissue (including a biopsy or autopsy specimen, such as a tumor biopsy) or can include a cell (whether a primary cell or cultured cell) or medium conditioned by any cell, tissue or organ. In some examples, a biological sample can be a nuclear extract. In some examples, a biological sample can be bacterial cytoplasm. In other examples, a sample can be a test sample. For example, a test sample can be a cell, a tissue or cell pellet section prepared from a biological sample obtained from a subject. In an example, the subject can be one that is at risk or has acquired a particular condition or disease. In certain embodiments, the sample can be cells isolated from whole blood or cell isolated from histological thin sections. Illustrative biological samples include nanoscale biological samples (e.g., containing low- or subnanogram (e.g., less than about 1 ng) amounts of protein which may be processed in a single nanowell or subdivided into multiple nanowells).



**[0035]** In the present invention, the sample is a biological sample and the biological sample is a tissue, and the tissue may be fixed. Tissues may be fixed by either perfusion with or submersion in a fixative, such as an aldehyde (such as formaldehyde, paraformaldehyde, glutaraldehyde, and the like). Other fixatives include oxidizing agents (for example, metallic ions and complexes, such as osmium tetroxide and chromic acid), protein-denaturing agents (for example, acetic acid, methanol, and ethanol), fixatives of unknown mechanism (for example, mercuric chloride, acetone, and picric acid), combination reagents (for example, Carnoy's fixative, methacarn, Bouin's fluid, B5 fixative, Rossman's fluid, and Gendre's fluid), microwaves, and miscellaneous (for example, excluded volume fixation and vapor fixation). Additives also may be included in the fixative, such as buffers, detergents, tannic acid, phenol, metal salts (for example, zinc chloride, zinc sulfate, and lithium salts), and lanthanum.

**[0036]** The method for preparing a biological sample includes displacing a volume of biological sample to a single reactor vessel. The volume of biological sample is a non-zero amount less than 1  $\mu\text{L}$ . In exemplary embodiments, the volume of biological sample may be a non-zero amount less than about 500 nL, less than about 400 nL, less than about 300 nL, less than about 200 nL, less than about 190 nL, less than about 180 nL, less than about 170 nL, less than about 160 nL, less than about 150 nL, less than about 140 nL, less than about 130 nL, less than about 120 nL, less than about 110 nL, less than about 100 nL, less than about 90 nL, less than about 80 nL, less than about 70 nL, less than about 60 nL, less than about 50 nL, less than about 40 nL, less than about 30 nL, less than about 20 nL, less than about 10 nL, or less than about 1 nL. In particular embodiments, the biological sample comprises about 50 nL.

**[0037]** In other embodiments, the biological sample may be measured by their confluence. Confluency refers to cells in contact with one another on a surface (e.g., a tissue culture vessel, a petri dish, a well, and the like). For example, it can be expressed as an estimated (or counted) percentage, e.g., 10% confluency means that 10% of the surface, e.g., of a tissue culture vessel, is covered with cells, 100% means that it is entirely covered. For example, adherent cells grow two dimensionally on the surface of a tissue culture well, plate or flask. Non-adherent cells can be spun down, pulled down by a vacuum, or tissue culture medium aspiration off the top of the cell population, or removed by aspiration or vacuum removal from the bottom of the vessel.

**[0038]** In examples not part of the present invention, the biological sample may include HeLa cells, A549 cells, CHO cells or MCF7 cells, K562 cells, or THP-1 cells, microbial cells, plant cells, or virtually any other biological material.

**[0039]** In other examples not part of the present invention, the biological sample may include of primary or immortalized cells. Examples include but are not limited to, mesenchymal stem cells, lung cells, neuronal cells, fibroblasts, human umbilical vein (HUVEC) cells, and human embryonic kidney (HEK) cells, primary or immortalized hematopoietic stem cell (HSC), T cells, natural killer (NK) cells, cytokineinduced killer (CIK) cells, human cord blood CD34+ cells, B cells. Non limiting examples of T cells may include CD8+ or CD4+ T cells. In some aspects, the CD8+ subpopulation of the CD3+ T cells are used. CD8+ T cells may be purified from the PBMC population by positive isolation using anti-CD8 beads.

**[0040]** The biological sample includes tissues, including but not limited, liver tissue, brain tissue, pancreatic tissue, breast cancer tissue, or plant tissue.

#### Biological sample pre-preparation

**[0041]** The biological sample is collected and prepared using standard techniques. In examples not part of the present invention, cultured cells are collected and centrifuged. The pellet is then washed and re-suspended. The suspended cells are concentration to obtain desired cell numbers. In embodiments, the desired number of cells can be readily optimized. In certain aspects, the number of cells is 1 cell, 2 cells, 3 cells, 4 cells, 5 cells, 6 cells, 7 cells, 8 cells, 9 cells, 10 cells, 15 cells, 20 cells, 30 cells, 40 cells, 50 cells, 100 cells, 200 cells. In further embodiments, the sample is then adjusted to obtain a nano liter cell suspension (e.g., a 50 nL cell suspension).

**[0042]** In the present invention, the biological sample is a laser microdissected tissue. The tissue is less than about 1000  $\mu\text{m}$ , less than about 900  $\mu\text{m}$ , less than about 800  $\mu\text{m}$ , less than about 700  $\mu\text{m}$ , less than about 600  $\mu\text{m}$ , less than about 500  $\mu\text{m}$ , less than about 400  $\mu\text{m}$ , less than about 300  $\mu\text{m}$ , less than about 200  $\mu\text{m}$ , less than about 100  $\mu\text{m}$ , less than about 50  $\mu\text{m}$ , less than about 40  $\mu\text{m}$ , less than about 30  $\mu\text{m}$ , less than about 20  $\mu\text{m}$ , less than about 10  $\mu\text{m}$ , less than about 5  $\mu\text{m}$ .

#### *Processing the biological sample*

**[0043]** As described herein, a robotic nanoliter dispensing platform 100 can be employed to perform sample processing steps associated with bottom-up proteomics (e.g., robotic platform (Vandermarlier, E et al)). As shown in FIG. 1, dispensing platform 100 can include a translatable stage 102 configured to receive a chip 104. The chip 104 can be configured to retain biological samples and reagents dispensed therein for further processing. The robotic platform 100 can be configured to provide submicron positioning accuracy and capacity for accurately handling picoliter volumes to dispense cells and reagents into reactor vessels formed in the chip 104 for further processing (e.g., to yield a processed sample).and to retrieve samples for subsequent analysis.

**[0044]** Biological samples and/or reagents can be dispensed in the chip 104 via a syringe pump 206 including a picoliter dispensing tip 110 under the control of a controller, which can include one or more user interfaces for receiving commands from a user. The syringe pump 106 can be in fluid communication with a source of the biological samples (not shown) and one or more reservoirs 114 containing reagents. The platform 100 can further include a camera 116 or other imaging

5 device for viewing dispensing of the biological samples and/or reagents.  
**[0045]** In embodiments, the total volume of biological samples and/or reagents can be less than 200 nL (in particular embodiments, a non-zero amount of less than 200 nL). Embodiments of the method can dramatically reduce surface contact to minimize sample loss while also enhancing reaction kinetics.

10 **[0046]** In certain embodiments, the nanoPOTS platform described herein can reduce the total processing volumes (for example, the volume of the biological sample plus the total volume of all the reagents for processing) from the conventional tens or hundreds of microliters to less than 5,000 nL, less than 3,000 nL, less than 2,000 nL, less than 1,000 nL, less than 500 nL, less than 400 nL, less than 300 nL, less than 200 nL, less than 100 nL, less than 50 nL, less than 20 nL, less than 10 nL, less than 5 nL.

15 **[0047]** As described herein, the biological sample is processed in a single reactor vessel to yield a processed sample. The single reactor vessel avoids the need to transfer samples to multiple reactor vessels for processing and therefore avoids the corresponding sample losses that such steps incur.

**[0048]** In embodiment, and as described herein the biological sample is processed in a single reactor vessel, a cocktail containing a reducing agent (e.g., dithiothreitol) is added and the sample is incubated. This allows for lysing, extraction, and denaturation of the proteins, and to reduce disulfide bonds in a single step.

20 **[0049]** In certain aspects, the pH is between 5 and 10, preferably 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10. More preferably, a solution pH value of 8 may be used.

**[0050]** In an exemplary processing step, a protease is then added to the single reactor vessel (e.g., trypsin or LysC). The addition of a protease allows digestion of the polypeptides.

25 **[0051]** In some examples, the process may be performed in a humidity-controlled chamber. In some examples, the humidity-controlled chamber is maintained at a relative humidity within the range from about 80% to about 100%, e.g., at about 95% humidity. For chemical or enzymatic processing steps that require extended reaction times at room temperature or elevated temperatures, a cover plate may be employed to minimize evaporation.

**[0052]** In some aspects, the single reactor vessel is sealed during incubation times (e.g., after the addition of a reducing agent). The sealed single reactor vessel aids in minimizing evaporation and therefore sample loss.

30 **[0053]** Optionally, methods disclosed herein may include steps such as washing steps to maximize recovery (e.g., into a capillary). In aspects, the capillary can be fused or sealed from the external environment and stored. In an example, the processed biological sample is washed with a buffer (e.g., with water containing formic acid), and in some examples, multiple washing steps are performed, for example, 2 washing steps. Storage of the processed biological sample in the capillary may be short term (e.g., at about -20°C for less than 6 months) or long term (e.g., at about -70°C for greater

35 than 12 months).  
**[0054]** In certain aspects, the chip can be inverted during sample incubation to prevent the sample from settling on the reactor vessel surface (see **FIGS. 34A** and **34B**). For example, droplets containing the biological sample may hang below the reactor vessel surface.

40 **[0055]** In a further embodiment of the disclosed methods, the processed biological sample can be subjected to mass spectrometry for identification, characterization, quantification, purification, concentration and/or separation of polypeptides without further steps of sample preparation. Since embodiments of the disclosed sample preparation methods can be performed in a single reactor vessel without filtering, precipitation or resolubilization steps, it can facilitate efficient analysis of cell-limited samples.

#### 45 *Analysis of the biological sample*

**[0056]** Embodiments of the disclosed methods, as described herein, can have broad application in the fields of proteomics, metabolomics, and lipidomics, as such robust analysis from small samples have not been achievable using previously developed procedures. However this description of potential applications is non-limiting and one skilled in

50 the art will appreciate that embodiments of the disclosure can be employed in other applications without limit.  
**[0057]** As described herein, biological samples processed according to embodiments of the disclosed methods may be analyzed using a variety of methods. In particular examples, the methods used to analyze the processed biological sample can include, but are not limited to, quantitative proteomic analysis methods. In embodiments, the processed biological sample may be analyzed mass spectrometry.

55 **[0058]** Mass spectrometry can utilize matrix-assisted laser desorption/ionization (MALDI), electrospray ionization (ESI), and other specialized mass spectrometry techniques. For example, MALDI mass spectrometry is a technique for the analysis of peptide mixtures resulting from proteolysis (e.g., digestion of proteins by trypsin). Embodiments of the methods disclosed herein can be used for top-down or bottom-up proteomics.

**[0059]** Chromatography can also be employed for peptide separation. Liquid chromatography or capillary electrophoresis can be coupled to mass spectrometry, particularly with an electrospray ionization source. In the case of proteomic analysis using liquid chromatography/mass spectrometry, a transfer device (e.g., a transfer capillary) can be directly coupled to a solid-phase microextraction column. The microextraction column can, in turn, be coupled to the head of the liquid chromatography column. Alternatively, the transfer capillary may also be directly coupled to the head of the liquid chromatography column.

**[0060]** In embodiments, the analyzing the processed biological sample can identify unique species, including but not limited to proteins or fragments thereof, lipids, or metabolites.

**[0061]** In embodiments, analyzing the processed biological sample can identify at least about 1,000 unique species (e.g., proteins or fragments thereof, lipids, and/or metabolites). In additional embodiments, the processed biological sample can identify at least 2,000 unique species, at least 3,000 unique species, at least 4,000 unique species, at least 5,000 unique species, at least 7,000 unique species. In other embodiments, the number of unique species identified can be at least 500 or more proteins and/or 100 or more metabolites or lipids.

**[0062]** In embodiments, the methods described herein can allow for the identification and quantitative measurements from less than about 200 cells (e.g., from the range of about 1 to about 50 mammalian cells). In particular embodiments, method described herein enables for identification of over 3,000 unique species from about 10-50 mammalian cells.

**[0063]** In another embodiment, nanowell sample processing can be coupled with laser-capture microdissection (LCM) for deep proteome analysis of heterogeneous tissue thin sections with <100  $\mu\text{m}$  resolution. Deciphering the cellular interactions that drive disease within tissue microenvironment can be beneficial for understanding tumor formation and propagation, developing drug targets, and designing personalized treatment regimens.

**[0064]** While LCM can differentiate and isolate subsections of tissue with high specificity, sample requirements for proteomics can limit the resolution of LCM to large or pooled thin sections comprising thousands or tens of thousands of cells and millimeter or larger dimensions. Such heterogeneous tissues can confound molecular analysis due to a blurring of cellular constituents and their respective contributions. In contrast, embodiments of the presently disclosed methods can provide proteomic analysis of LCM-isolated tissues by reducing sample size by approximately 2 orders of magnitude, to less than about 50 cells, which can enable both high resolution proteomic imaging (e.g., less than about 100  $\mu\text{m}$ ) as well as isolation of specific tissues from much smaller samples, such as smears from fine needle aspiration biopsies.

**[0065]** LCM can be used to excise and transfer select tissue from thin section to the nanowell. As an example, an LCM (e.g., Zeiss PALM Microbeam LCM®) can be used to excise selected tissue from fresh frozen or archived formalin-fixed, paraffin embedded (FFPE) thin sections (e.g., obtained from Conversant Bio, Inc.). The Zeiss system can provide submicron resolution and it can be equipped with laser-pressure catapulting to eject excised samples to a variety of substrates, including centrifuge tube lids and slides (e.g., 25  $\times$  75 mm). The Zeiss LCM can be compatible with standard glass slides for archived specimens as well as LCM-dedicated polymer membrane-coated slides.

**[0066]** The nanowells can be configured for compatibility with the 25  $\times$  75 mm form factor. This can allow for direct coupling and facilitate transfer from thin sections to the nanowells. As discussed in greater detail below, the nanowells can have a diameter of about 0.5 mm to about 1.5 mm. The spacing between the nanowell slide and the thin section slide may be adjusted to achieve the requisite transfer accuracy. Nanowell surface treatments may be implemented as needed to ensure adhesion of the catapulted tissue upon contact. As an alternative approach, excised samples can be catapulted into centrifuge tube caps and micromanipulationbased strategies can be used to transfer the sample to the nanowell.

**[0067]** In the present invention, sample processing is seamlessly integrated with LCM by providing a capture liquid in or on a reactor vessel. This method can avoid manual transfer of dissected tissues to the nanowells that is required in a conventional LCM system. In a conventional LCM system, after being dissected, tissue pieces may be collected into microtubes by gravity or catapulted into tube caps prefilled with extraction solution or adhesive coating, depending on the instrument vendor and configuration. However, these collection approaches cannot be automatically integrated with a nanoPOTS system because the rapid evaporation of nanoliter-scale extraction solution and the prohibitive absorptive losses of proteins on the adhesive silicone coating. Utilizing a sacrificial capture medium in the nanowells addresses this challenge.

**[0068]** The capture liquid has an ultra-low vapor pressure (less than or equal to 0.8 mbar at room temperature), and evaporates very slowly under ambient conditions, which allows for long working times and uninterrupted sample collection. For example, as shown in **FIG. 30A**, the evaporation times of 100 nL to 300 nL dimethyl sulfoxide (DMSO) droplets were 194 min to 416 min, which were >50 times longer than for water droplets. Such prolonged times are sufficient to collect up to hundreds of tissue samples in each chip. The capture liquid can be completely removed by gentle heating or vacuum, eliminating any possible interference during subsequent sample processing and analysis steps. Compared with other low-vapor-pressure solvents such as dimethylformamide, the capture liquid should have a lower toxicity, thus enabling its use as a storage solvent for cells. An illustrative capture liquid is dimethyl sulfoxide (DMSO). In addition to having an ultra-low vapor pressure and lower toxicity, the freezing point of DMSO is 18.5 °C, which should facilitate chip

and sample transfer between histology and analytical labs without the risk of sample mixing or losses during shipping. In addition, it has been presently found that DMSO significantly increases the sensitivity of protein identification of brain tissues, which may be ascribed to improved protein extraction efficiency as explained in more detail below. The amount of capture liquid provided in each nanowell may be sufficient to cover a portion of, or the entire surface, of the nanowell. For example, the capture liquid may be present in an amount of at least 1 nL to 1000 nL.

#### Molecular characterization and disease profiles

**[0069]** Embodiments of the methods described herein can be used for molecular characterization of tissue cellular heterogeneity or pathology in a variety of diseases. Exemplary diseases can include, but are not limited to, inflammatory diseases, metabolic diseases, cancers, neoplasias, and the like.

**[0070]** As used herein, metabolic disease can include its customary and ordinary meaning and can refer to diabetes, including type II diabetes, insulin-deficiency, insulin-resistance, insulin-resistance related disorders, glucose intolerance, syndrome X, inflammatory and immune disorders, osteoarthritis, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver, abnormal lipid metabolism, neurodegenerative disorders, sleep apnea, hypertension, high cholesterol, atherogenic dyslipidemia, hyperlipidemic conditions such as atherosclerosis, hypercholesterolemia, and other coronary artery diseases in mammals, and other disorders of metabolism. For example, the methods as used herein can be used in characterizing type 1 or type 2 diabetes.

**[0071]** As used herein, neoplasia can include its customary and ordinary meaning and can refer to a disease or disorder characterized by excess proliferation or reduced apoptosis. Illustrative neoplasms for which the embodiment may be used include, but are not limited to pancreatic cancer, leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin's disease, non-Hodgkin's disease), Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors such as sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, nile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).

#### Definitions

**[0072]** While various embodiments and aspects of the present disclosure are shown and described herein, it will be obvious to those skilled in the art that such embodiments and aspects are provided by way of example only. Numerous variations, changes, and substitutions can occur to those skilled in the art without departing from the disclosed embodiments. It should be understood that various alternatives to the embodiments described herein may be employed.

**[0073]** The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in the application including, without limitation, patents, patent applications, articles, books, manuals, and treatises are hereby expressly incorporated by reference in their entirety for any purpose.

**[0074]** Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which embodiments of the disclosure pertains.

**[0075]** As used herein, the term "biological sample" can include its customary and ordinary meaning and can refer to a sample obtained from a biological subject, including sample of biological tissue or fluid origin obtained in vivo or in vitro. Such samples can be, but are not limited to, body fluid (e.g., blood, blood plasma, serum, or urine), organs, tissues, fractions, and cells isolated from mammals including, humans. Biological samples also may include sections of the biological sample including tissues (e.g., sectional portions of an organ or tissue). Biological samples may also include extracts from a biological sample, for example, an antigen from a biological fluid (e.g., blood or urine).

**[0076]** A biological sample may be of prokaryotic origin or eukaryotic origin (e.g., insects, protozoa, birds, fish, or reptiles). In some embodiments, the biological sample can be mammalian (e.g., rat, mouse, cow, dog, donkey, guinea pig, or rabbit). In certain embodiments, the biological sample can be of primate origin (e.g., example, chimpanzee, or human).

**[0077]** The transitional term "comprising," which is synonymous with "including," "containing," or "characterized by,"

is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. By contrast, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps "and those that do not materially affect the basic and novel characteristic(s)" of the claimed embodiments.

**[0078]** "Detectable moiety" or a "label" can include its customary and ordinary meaning and it can refer to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include  $^{32}\text{P}$ ,  $^{35}\text{S}$ , fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin-streptavidin, dioxigenin, haptens and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules with a sequence complementary to a target. The detectable moiety can generate a measurable signal, such as a radioactive, chromogenic, or fluorescent signal, that can be used to quantify the amount of bound detectable moiety in a sample. Quantitation of the signal can be achieved by, e.g., scintillation counting, densitometry, mass spectrometry, and/or flow cytometry.

**[0079]** By "FFPE" can refer to formalin fixed paraffin embedded tissue. FFPE samples can be derived from tissues (often suspected tumor samples) that are fixed with formalin to preserve structural-spatial and biomolecule characteristics (e.g., cytoskeletal and protein structure) and then embedded in a type of paraffin wax so the tissue can be sliced. Formalin can irreversibly cross-link proteins via the amino groups, thus preserving the structural integrity of the cells so they can be stained with dyes or with immunostains used to analyze for abnormalities in the tissue that indicate altered cellular conditions, e.g., cancer. However, the effect of these cross-linking fixatives on the RNA and DNA nucleic acids within the sample can be detrimental to the sensitivity and specificity achievable in current molecular assays e.g., molecular assays which use DNA or RNA derived from FFPE samples. Additionally, samples may be prepared using non-formalin reagents, including, for example, glutaraldehyde, mercurial, oxidizing agents, alcohols, and picrates.

**[0080]** The term "hydrophilic surface" can include its customary and ordinary meaning and it can refer to a surface to have native hydrophilic property such as glass or fused silica, or which either hydrophilic compounds are covalently or non-covalently attached or which is formed of a polymer that has hydrophilic properties. In embodiments, the polymer with hydrophilic properties can be an organic polymer, (e.g., polyacrylamide, polyacrylic acid, polyacrylimide, polyelectrolytes, polyethylenimine, polyethyleneglycol, polyethylenoxid, polyvinylalcohol, polyvinylpyrrolidone polystyrenesulfonic acid, copolymers of styrene and maleic acid, vinyl methyl ether malic acid copolymer, and polyvinylsulfonic acid.

**[0081]** As used herein, the singular terms "a," "an," and "the" include the plural reference unless the context clearly indicates otherwise.

## EXAMPLES

### Example 1: Nanodroplet

#### *NanoPOTS platform design and operation*

**[0082]** An exemplary nanoPOTS chip, also referred to as a platform or chip 200, is illustrated in FIG. 2. The chip 200 can include a substrate 202, a spacer 204, one or more sealing membrane 206, and a cover 210. When the chip is assembled, the spacer 204 can overlie the substrate 202, the sealing membrane 206 can overlie the spacer 204, and the cover 210 can overlie the sealing membrane 206.

**[0083]** The substrate 202, the spacer 204, and the cover 210 can be formed from a material that is transparent to optical light (e.g., glass). Forming the substrate 202 from glass can facilitate microscopic imaging of samples and minimize protein and peptide adsorption relative to many other materials due to its hydrophilicity and reduced surface charge at low pH (Zhu, Y, et al.).

**[0084]** As discussed in greater detail below, the substrate 202 includes a physical and/or chemical pattern 212 that defines at least one reactor vessel having one or more hydrophilic and optionally hydrophobic surfaces configured for containment of a biological sample. The hydrophilic surfaces have a non-zero total surface area less than 5 mm<sup>2</sup>.

**[0085]** The spacer 204 can contain a first aperture 204a and the sealing membrane 206 can include a second aperture 206a. The first and second apertures 204a, 206a can be dimensioned to accommodate the pattern 212 of reactor vessels when the chip 200 is assembled. As an example, at least the first aperture 204a of the spacer can surround the pattern 212 of reactor vessels.

**[0086]** The sealing membrane 206 can be interposed between the spacer 204 and the cover 210 and it can be configured to form a fluid-tight seal between the spacer 204 and the cover 210. In other embodiments, not shown, the sealing membrane can be interposed between the substrate and the spacer. Formation of fluid-tight seals using the sealing membrane can minimize evaporation of reactor vessel contents when performing incubation during sample preparation, as discussed below. Optionally, other sealing mechanisms can be employed and the sealing membrane can be omitted. For example, the cover 210 can be pre-coated with a layer of sealing membrane such as PDMS (polydimethylsiloxane).

**[0087]** FIGS. 3A-3E illustrate an exemplary forming the pattern 212 by photolithography. In FIG. 3A, a substrate 300 coated with an anti-reflective coating 302 and photoresist 304 is illustrated. A photomask 306 can be used in conjunction with light 310 (e.g., ultraviolet light) to transfer a geometric pattern of the photomask 306 to the photoresist 304. The anti-reflective coating 302 can be configured to control reflection and absorption of the light 310. As shown in FIGS. 3B-3C, the portions of the photomask 306 and anti-reflective coating 302 outside the transferred pattern can be removed by a chemical etching to yield a patterned substrate 312 that includes pillars 314 defining wells 316 therebetween of predetermined depth within the substrate 300. The photomask 306 and anti-reflective coating 302 remaining on the upper surface of the pillars 312 are removed with further chemical etching, as shown in FIGS. 3D-3E.

**[0088]** FIGS. 4A-4B illustrate examples of the patterned substrate 412 defining reactor vessels configured for multiple-step proteomic sample processing. As shown in FIG. 4A, a hydrophobic coating can be deposited on the patterned substrate 412, adjacent to the pillars 414, to form a hydrophobic surface 402. A hydrophilic coating can be deposited on the patterned substrate 412 on the upper surface of the pillars 414 to form a hydrophilic surface 404. Alternatively, when the substrate is formed from a hydrophilic material, a hydrophobic coating can be omitted and the bare surface of the substrate can form the hydrophilic surface 404. So configured, the upper surface of each pillar 414 with the hydrophilic surface 404 can define the lateral boundary of respective reactor vessels 400. In certain examples, the patterned pillars 414 can reduce surface area contact relative to the use of concave wells.

**[0089]** Conversely, as shown in FIG. 4B, the locations of the hydrophobic and hydrophilic coatings can be reversed. That is, the hydrophilic coating can be deposited on the patterned substrate 412 adjacent to the pillars 414 (e.g., within the wells 416) to form the hydrophilic surface 404. Alternatively, as discussed above, when the substrate is formed from a hydrophilic material, a hydrophobic coating can be omitted and the bare surface of the substrate can form the hydrophilic surface 404. Likewise, the hydrophobic coating can be deposited on the patterned substrate 412 on the upper surface of the pillars 414 to form the hydrophobic surface 402. So configured, the wells 416 with the hydrophilic surface 404 can define the lateral boundary of respective reactor vessels 410.

**[0090]** In another example, as illustrated in FIG. 5, a patterned substrate 500 can be formed by a pattern of hydrophobic surfaces 402 and hydrophilic surfaces 404 alone, without pillars 414 or wells 416. The hydrophobic surfaces 402 and the hydrophilic surfaces can be provided as discussed above and they can define the lateral extent of the one or more reactor vessels 420.

**[0091]** In certain embodiments, as illustrated in FIGS. 34A and 34B, a chip 600 that includes a substrate 601 and reactor vessel pillars 602 is inverted during processing of a biological sample. A droplet 603 of a capture liquid suspends from the hydrophilic surface of the reactor vessel pillar 602. The capture liquid droplet 603 contains a biological sample 604 that can be subjected to processing.

**[0092]** In an example not part of the present invention, the RapiGest-based one-pot protocol (Waters, Milford, USA) was adapted for proteomic sample preparation with minimal modification (FIGS. 7-8). Briefly, after cells or other tissue samples were deposited into each chamber of the array, microscopic imaging was used for sample size quantification (cell number, tissue dimensions, etc.). A cocktail containing RapiGest and dithiothreitol was added and incubated at 70°C to lyse cells, extract and denature proteins, as well as reduce disulfide bonds in a single step. The proteins were alkylated and digested using a two-step enzymatic hydrolysis. Finally, the solution was acidified to cleave and inactivate the RapiGest surfactant. Manipulations were conducted in a humidified chamber, and the cover plate was sealed to the nanowell chip during extended incubation steps to minimize evaporation of the nanoliter droplets. The prepared sample was collected into a fused-silica capillary, followed by a two-step wash of the nanowell to maximize recovery (FIG. 7). The collector capillary can be fully sealed and stored in a freezer for months without observable sample loss. The capillary also simplified downstream solid-phase extraction-based cleanup and LC-MS analysis by enabling direct coupling with standard fittings.

#### *Sensitivity and proteome coverage*

**[0093]** The sensitivity by processing 10-141 cultured HeLa cells with nanoPOTS (FIG. 1) was evaluated. Three different blank controls were used to confirm negligible carryover and contamination from the SPE and LC columns, reagents, and cell supernatant, respectively (FIG. 15). In contrast to the control samples, all cell-containing samples showed feature-rich base peak chromatogram profiles, and the number of peaks and their intensities increased with the number of cells (FIG. 13A-13C). The percentage of peptides having tryptic cleavage sites ranged from 97.4% to 97.9%, while the percentage of peptides having tryptic missed cleavage sites ranged from 23.2% to 27.8% (FIG. 22), indicating a digestion efficiency that is on par with conventional bulk processing (Wang, N. et al). The average peptide coverage based on MS/MS identification ranged from 7,364 to 17,836, and protein coverage ranged from 1,517 to 3,056 for triplicate groups comprising 10-14, 37-45 and 137-141 cells, respectively (FIG. 14A and 14B). When the Match Between Runs (MBR) algorithm of Maxquant (Shen, Y et al.) was used, 85% of the identified proteins were found to be common to all samples (FIG. 24A-24C), indicating more proteins could likely be identified and quantified from the smaller samples if a larger reference library were used, or an appropriate accurate mass and time (AMT) tag database (Tyanova S, et

al. 2016) were available. The ability to identify an average of 3,092 proteins in as small as ~10 cells (FIG. 24A-24C) represents a >500-fold decrease in sample size to achieve similar proteome coverage relative to previously reported methods (Sun, X et al, Chen, W et al., Wannanders, L. et al, Huang, E. et al, and Wang, N. et al) (Table 1, below).

Table 1: Reported protein identification results with cell number lower than 2,000

Cell #	Cell type	Identified protein #	Sample preparation method
100	DLD-1	635	High temperature trypsin digestion <sup>1</sup>
250	DLD-1	759	High temperature trypsin digestion <sup>1</sup>
500	DLD-1	1060	High temperature trypsin digestion <sup>1</sup>
	MCF-7	187	Acetone precipitation <sup>2</sup>
	Hela	905	FASP <sup>3</sup>
1000	MCF-7	271	Acetone precipitation <sup>2</sup>
	Hela	1536	FASP <sup>3</sup>
2000	HEK 239T	1270	Spin tip <sup>4</sup>

**[0094]** To understand the absolute sensitivity of the nanoPOTS-LC-MS platform, the proteins were matched identified from 10-14 cells to the reported databases containing protein copy numbers per HeLa cell (Wisniewski, J. et al 2014, and Volpe, P. et al).. In the first database, the absolute copy numbers of 40 proteins in HeLa cell were precisely quantified using spiked-in protein epitope signature tags (PrEST) in combination with SILAC-based isotopic labeling (Volpe, P. et al). Thirty-four of the 40 proteins were identified, and the 6 missed proteins were low in abundance. The corresponding protein copy number per cell ranged from about  $5 \times 10^4$  to about  $2 \times 10^7$  (Table 2), with 3 expressed at  $< 10^5$  copies/cell. Considering the highly reliable values obtained using the PrEST-SILAC method, the detection limit of nanoPOTS for protein is  $< 5 \times 10^5$  copies, or  $< 830$  zmol.

Table 2. Copy numbers per HeLa cell for proteins identified from 10-14 cells (copy number obtained from PrEST-SILAC method (Li, et al. and Zeiler, M. et al.).

Protein Name	Gene Names	Protein copy number per HeLa cell
Pre-mRNA-splicing regulator WTAP	WTAP	49,143
ATPase family AAA domaincontaining protein 2	ATAD2	63,835
Poly [ADP-ribose] polymerase 4	PARP4	63,971
Carbonyl reductase [NADPH] 3	CBR3	79,823
Endoplasmic reticulum lipid raftassociated protein 2	ERLIN2	149,867
THO complex subunit 1	THOC1	204,962
28S ribosomal protein S23, mitochondrial	MRPS23	223,198
Hepatocellular carcinoma-associated antigen 59	C9orf78	265,003
COP9 signalosome complex subunit 5	COPS5	323,791
Nucleoprotein TPR	TPR	357,637
AFG3-like protein 2	AFG3L2	369,737
28S ribosomal protein S35, mitochondrial	MRPS28	422,825
Prefoldin subunit 1	PFDN1	476,849
Cytosolic acyl coenzyme A thioester hydrolase	ACOT7	512,746

(continued)

	Protein Name	Gene Names	Protein copy number per HeLa cell
5	Cytochrome b-c1 complex subunit 1, mitochondrial	UQCRC1	1,022,450
	26S protease regulatory subunit 6A	PSMC3	1,062,048
	Eukaryotic translation initiation factor 3 subunit 6	EIF3E	1,067,627
10	FACT complex subunit SSRP1	SSRP1	1,095,695
	Ras GTPase-activating-like protein IQGAP1	IQGAP1	1,296,511
	SRA stem-loop-interacting RNA-binding protein,	SLIRP	1,397,500
15	Purine nucleoside phosphorylase	PNP	1,555,814
	Heat shock 70 kDa protein 4	HSPA4	1,646,549
	14-3-3 protein sigma	SFN	1,870,568
20	Flap endonuclease 1	FEN1	2,019,699
	Enoyl-CoA hydratase, mitochondrial	ECHS1	2,105,336
	Transitional endoplasmic reticulum ATPase	VCP	2,719,254
25	Fatty acid synthase	FASN	3,536,145
	T-complex protein 1 subunit beta	CCT2	4,479,130
	ATP synthase subunit beta, mitochondrial	ATP5B	4,511,967
	Peroxiredoxin 6	PRDX6	8,781,079
30	Peptidyl-prolyl cis-trans isomerase B	PPIB	10,502,199
	Vimentin	VIM	22,886,339

**[0095]** In the second database, a total of >5,000 proteins in HeLa cells were quantified using a histone-based 'proteomic ruler' and label-free quantitation based on MS intensities (Wisniewski, J. 2014). 2,892 of these proteins matched the proteins identified in the 10-14-cell samples, and the distribution of copy number per cell are shown in FIG. 16A and 16B. The results are biased to high-abundance proteins due to the use of only ~10 cells. The median copy number within our samples was  $\sim 2.5 \times 10^5$ , which is approximately 4 times higher than the reference value (Wisniewski, J. et al 2014). Importantly, a number of low-abundance proteins were identified, including 125 proteins with copy numbers below 10,000 and 10 proteins below 1,000 (FIG. 16A and 16B). These results indicate that the detection limit of the nanoPOTS-LC-MS platform may be below 16 zmol. The results also show the great potential of the nanoPOTS platform for single cell proteomics with further improvement in sensitivity by optimizing processing volumes, miniaturizing the LC separation, and improving MS instrumentation.

#### Reproducibility and quantitation

**[0096]** The reproducibility of nanoPOTS processing was evaluated using MS<sup>1</sup> intensity-based label-free quantification at both the peptide and the protein levels. The MBR analysis produced over 13,194 quantifiable peptides and 2,674 protein groups (FIG. 24A-24C). Median coefficients of variance (CVs) were  $\leq 20.4\%$  (peptide level) and 21.6% (protein level) for all the three cell loading groups (FIG. 17A-17D). Peptide and protein intensities spanning more than 4 orders of magnitude were observed (FIG. 17A-17D), indicating that dynamic range and proteome depth were substantially retained relative to bulk analyses. Pairwise analysis of any two samples with similar cell loadings showed Pearson correlation coefficients from 0.91 to 0.93 (FIG. 17A-17D) at the peptide level. Protein LFQ intensity revealed higher correlations with coefficients of 0.98 to 0.99 (FIG. 17A-17D). These data suggest that label-free quantification is feasible for far smaller proteomic samples than have been previously accessible.



## Methods

### Reagents and chemicals:

**[0097]** Deionized water (18.2 M $\Omega$ ) was purified using a Barnstead Nanopure Infinity system (Los Angeles, USA). Dithiothreitol (DTT) and iodoacetamide (IAA) were purchased from Thermo Scientific (St. Louis, USA) and freshly prepared in 50 mM ammonium bicarbonate buffer each day before use. RapiGest SF surfactant (Waters, Milford, USA) was dissolved in 50 mM ammonium bicarbonate buffer with a concentration 0.2% (m/m), aliquoted, and stored at -20 °C until use. Trypsin (MS grade) and Lys-C (MS grade) were products of Promega (Madison, USA). Other unmentioned reagents were obtained from Sigma-Aldrich (St. Louis, USA).

### Fabrication and assembly of the nanowell chip:

**[0098]** The photomask was designed with AutoCAD and printed with a direct-write lithography system (SF-100, Intelligent Micro Patterning LLC, St. Petersburg, USA). An array of 3  $\times$  7 spots with diameters of 1 mm and a spacing of 4.5 mm was designed on a 25 mm  $\times$  75 mm glass slide (soda lime) that was pre-coated with chromium and photoresist (Telic Company, Valencia, USA). After photoresist exposure (FIG. 3A), development, and chromium etching (Transene, Danvers, USA; FIG. 3B), the glass slide was hard baked at 110 °C for 10 min. The back side of the slide was protected with packing tape and the glass substrate surface was etched around the patterned photoresist/Cr features using wet etching solution containing 1 M HF, 0.5 M NH<sub>4</sub>F, and 0.75 M HNO<sub>3</sub> at 40 °C for 10 min to reach a depth of 10  $\mu$ m (FIG. 3C). The remaining photoresist was removed using AZ 400T stripper. The glass slide was thoroughly rinsed with water, dried using compressed nitrogen, and further dried in an oven at 120 °C for 2 h. The chip surface was then cleaned and activated with oxygen plasma treatment for 3 minutes using a March Plasma Systems PX250 (Concord, USA). The glass surface that was not protected with Cr was rendered hydrophobic with a fluorosilane solution containing 2% (v/v) heptadecafluoro-1,1,2,2-tetrahydrodecyl)dimethylchlorosilane (PFDS) in 2,2,4-trimethylpentane (FIG. 3D) for 30 min. The residual silane solution was removed by immersing the chip in 2,2,4-trimethylpentane followed by ethanol. Remaining chromium was removed using chromium etchant (Transene), leaving elevated hydrophilic nanowells on a hydrophobic background (FIG. 3E).

**[0099]** The glass spacer was fabricated by milling a standard microscope slide (25 mm  $\times$  75 mm  $\times$  1 mm) with a CNC machine (Minitech Machinery Corporation, Norcross, USA). Epoxy was used to glue the patterned chip and the glass spacer together. The glass cover was fabricated by spin coating a thin layer of polydimethylsiloxane (PDMS) membrane (10- $\mu$ m thickness) onto a standard glass microscope slide of the same dimensions. Briefly, Dow Coming Sylgard 184 silicone base was mixed with its curing reagent at a ratio of 10:1 (w/w) and degassed for 20 min. The mixture was coated on the slide by spinning at 500 rpm for 30 s followed by 3000 rpm for 5 min (WS-650, Laurell Technologies, North Wales, USA). Finally, the PDMS membrane was cured at 70 °C for 10 hours. A piece of Parafilm (Bemis Company, Oshkosh, USA) was precisely cut to serve as moisture barrier between the glass spacer and the glass cover.

### Nanoliter-scale liquid handling system:

**[0100]** All sample and reagent solutions were delivered to the nanowells using a home-built liquid handling system with a metering precision of 0.3 nL. The liquid handling system is similar to those described previously (Zhu, Y. et al 2013, Zhu Y. et al 2015, and Zhu, Y. et al. 2014) and was composed of four parts including a 3D translation stage (SKR series, THK, Japan) for automated position control, a home-built high-precision syringe pump (KR series, THK, Japan) for liquid metering, a microscopic camera system (MQ013MG-ON, XIMEA Corp., Lakewood, USA) for monitoring the liquid handling process, and a tapered capillary probe for liquid dispensing. The capillary probe was fabricated by heating pulling a fused silica capillary (200  $\mu$ m i.d., 360  $\mu$ m o.d., Polymicro Technologies, Phoenix, USA) to generate a tapered tip (30  $\mu$ m i.d., 50  $\mu$ m o.d.). A home-built program with LabView (Version 2015, National Instruments, Austin, USA) was used to synchronously control the movement of the 3D stages and the liquid dispensing of the syringe pump. To minimize evaporation during the liquid handling procedure, the whole system was enclosed in a Lexan chamber maintained at 95% relative humidity.

**[0101]** The syringe pump was set at a withdraw rate of 9  $\mu$ L/min and an infusion rate of 3  $\mu$ L/min. The translation stages were operated at a start speed of 1 cm/s, a maximum speed of 30 cm/s, and an acceleration time of 0.5 s. In the typical setup, it took total  $\sim$  2 min to dispense one reagent to all the 21 droplets in single chip including the time for withdrawing reagent into the capillary probe, moving of the robotic stages, and dispensing 50 nL reagent into each droplet.

**[0102]** To meet the requirement of processing large number of samples in single experiment, the nanowells can be scaled up with the present photolithography-based microfabrication technique. Up to 350 nanowells can be fabricated on a 25 mm  $\times$  75 mm microscope slide and further scale-up is possible with larger substrates. The robot can be simply configured to fit different formats of nanowell array. Because of the high liquid handling speed, 350 droplets could be

addressed in <30 min.

#### Cell culture:

**[0103]** All cells were cultured at 37 °C and 5% CO<sub>2</sub> and split every 3 days following standard protocol. HeLa was grown in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS) and 1× penicillin streptomycin.

#### Laser capture microdissection of human pancreatic islets:

**[0104]** Ten-µm-thick pancreatic tissue slices were cut from OCT blocks using a cryo-microtome and mounted on PEN slides for islet dissection. Slides were briefly fixed with methanol, rinsed with H<sub>2</sub>O to remove OCT, and dehydrated using an alcohol gradient before placing in a desiccator to dry (8 minutes). Dehydrated and dried slides were placed on the stage of a laser microdissection microscope (Leica LMD7000). Islets were identified based on autofluorescence and morphology. Dissections were performed under a 10× objective. Laser dissected islets were collected in the cap of a 0.6-mL tube mounted underneath the slides. After dissection, samples were stored at -80 °C until further analysis.

#### Proteomic sample preparation in Eppendorf low-binding vial:

**[0105]** HeLa cells were collected in a 10 mL tube and centrifuged at 1200 rpm for 10 minutes to remove culture media. The cell pellet was further washed three times with 10 mL of 1× PBS buffer. The cells were then suspended in 1 mL PBS buffer and counted to obtain cell concentration. Eppendorf protein low-binding vials (0.5 mL) were used throughout the process. Cells were lysed at a concentration of 5×10<sup>5</sup>/mL in 0.1% RapiGest and 5 mM DTT in 50 mM ammonium bicarbonate (ABC). After heating at 70 °C for 30 min, the cell lysate was diluted in 50 mM ABC buffer and aliquoted to different vials with a volume of 5 µL. 5 µL of IAA solution (30 mM in 50 mM ABC) was dispensed to alkylate sulfhydryl groups by incubating the vials in the dark for 30 minutes at room temperature. 5 µL of Lys-C (0.25 ng in 50 mM ABC) was added and incubated at 37 °C for 4 h. 5 µL of Trypsin (0.25 ng in 50 mM ABC) was added and incubated overnight at 37 °C. Finally, 5 µL of formic acid solution (30%, v/v) were dispensed and allowed to incubate for 1 h at room temperature to cleave RapiGest surfactant for downstream analysis.

#### Proteomic sample preparation in nanodroplets:

**[0106]** Before use, the chip was washed with isopropanol and water to minimize contamination. The liquid handling system was configured to minimize cross contamination by adjusting the vertical distance between the probe tip and the nanowell surface, which was previously termed semi-contact dispensing (Zhu, Y. et al 2014).

**[0107]** For cultured cell samples, cells were collected in a 10 mL tube and centrifuged at 1200 rpm for 10 minutes to remove culture media. The cell pellet was further washed three times with 10 mL of 1× PBS buffer. The cells were then suspended in 1 mL PBS buffer and counted to obtain cell concentration. Cell concentrations were adjusted by serially diluting them in PBS to obtain different cell numbers in nanowells. After dispensing 50 nL of cell suspension into each nanowell, we observed that the distribution of cell numbers in nanowell was stochastic, especially for low concentration cell suspensions. Thus, the accurate cell number in each nanowell was counted using an inverted microscope and indexed to the two-dimensional spatial position of the corresponding nanowell. For LCM tissues, a high precision tweezer with a tip of 20 µm (TerraUniversal, Buellton, USA) was used to transfer tissue pieces from collection tubes into individual nanowells under a stereomicroscope (SMZ1270, Nikon, Japan). ImageJ software<sup>37</sup> was used to measure the area of LCM islets to calculate islet equivalents (IEQ) and cell numbers.

**[0108]** For sample preparation of cultured cells, 50-nL RapiGest (Yu et al. 2003) (0.2%) solution with 10 mM DTT in 50 mM ammonium bicarbonate (ABC) was added into the nanodroplets that had been preloaded with cells. For LCM tissue samples, 100 nL of RapiGest solution (0.1% in 50 mM ABC) containing 5 mM DTT was added. The cover was then sealed to the nanodroplet chip, which was incubated in 70 °C for 30 min to achieve cell lysis, protein denaturation, and disulfide reduction. In the second step, 50 nL of IAA solution (30 mM in 50 mM ABC) was dispensed to alkylate sulfhydryl groups by incubating the chip in the dark for 30 minutes at room temperature. In the third step, 50 nL enzyme solution containing 0.25 ng Lys-C in 50 mM ABC was added and incubated at 37 °C for 4 h for predigestion. In the fourth step, 50 nL of enzyme solution containing 0.25 ng trypsin in 50 mM ABC was added into each droplet and incubated overnight at 37 °C for tryptic digestion. Finally, 50 nL of formic acid solution (30%, v/v) was dispensed and allowed to incubate for 1 h at room temperature to cleave RapiGest surfactant for downstream analysis. To minimize liquid evaporation in nanowells, the chip was completely sealed during cell counting, incubation, and transfer procedures. During each dispensing step, the chip was opened and closed within the humidity chamber to minimize droplet evaporation. However, as the total dispensed volume in each droplet was 300 nL, and the final volume was typically <200 nL, some

evaporative losses clearly occurred. Some of these water losses were observed as condensation on the contactless cover upon cooling from the 70 °C protein extraction step, and the extended digestions at 37 °C also resulted in minor volume reductions. Such water losses have no negative effect on the performance of nanoPOTS platform, but could become limiting when further downscaling processing volumes.

#### Nanoliter-volume sample collection and storage:

**[0109]** Digested peptide samples in each nanowell were collected and stored in a section of fused silica capillary (5 cm long, 150  $\mu\text{m}$  i.d., 360  $\mu\text{m}$  o.d.). Before sample collection, the capillary was connected to the syringe pump and filled with water containing 0.1% formic acid (LC Buffer A) as carrier. A plug of air (10 nL, 0.5 mm in length) was aspirated into the front end of the capillary to separate sample from carrier. The capillary-to-nanowell distance was adjusted to ~20  $\mu\text{m}$  to allow majority of sample to be aspirated into the capillary. To achieve highest sample recovery, the nanowell was twice washed with 200-nL buffer A and the wash solutions were also collected in the same capillary. A section of capillary containing a train of plugs consisting of carrier, air bubble, sample, and wash solutions was then cut from the syringe pump. The capillary section was sealed with Parafilm at both ends and stored at -20 °C for short-term storage or -70 °C for long-term storage.

#### SPE-LC-MS setup:

**[0110]** The SPE precolumn and LC column were slurry-packed with 3- $\mu\text{m}$  C18 packing material (300-Å pore size, Phenomenex, Terrence, USA) as described previously (Shen, Y. et al 2004, and Shen, Y. et al. 2003). The SPE column was prepared from a 4-cm-long fused silica capillary (100  $\mu\text{m}$  i.d., 360  $\mu\text{m}$  o.d., Polymicro Technologies, Phoenix, AZ). The LC column was prepared from a 70-cm Self-Pack PicoFrit column with an i.d. of 30  $\mu\text{m}$  and a tip size of 10  $\mu\text{m}$  (New Objective, Woburn, USA). The sample storage capillary was connected to the SPE column with a PEEK union (Valco instruments, Houston, USA). Sample was loaded and desalted in the SPE precolumn by infusing buffer A (0.1% formic acid in water) at a flow rate of 500 nL/min for 20 minutes with an nanoACQUITY UPLC pump (Waters, Milford, USA). The SPE precolumn was reconnected to the LC column with a low-dead-volume PEEK union (Valco, Houston, USA). The LC separation flow rate was 60 nL/min, which was split from 400 nL/min with a nanoACQUITY UPLC pump (Waters, Milford, USA). A linear 150-min gradient of 5-28% buffer B (0.1% formic acid in acetonitrile) was used for separation. The LC column was washed by ramping buffer B to 80% in 20 minutes, and finally re-equilibrated with buffer A for another 20 minutes.

**[0111]** An Orbitrap Fusion Lumos Tribrid MS (ThermoFisher) was employed for all data collection. Electrospray voltage of 1.9 kV was applied at the source. The ion transfer tube was set at 150 °C for desolvation. S-lens RF level was set at 30. A full MS scan range of 375-1575 and Orbitrap resolution of 120,000 (at  $m/z$  200) was used for all samples. The AGC target and maximum injection time were set as 1E6 and 246 ms. Data-dependent acquisition (DDA) mode was used to trigger precursor isolation and sequencing. Precursor ions with charges of +2 to +7 were isolated with an  $m/z$  window of 2 and fragmented by high energy dissociation (HCD) with a collision energy of 28%. The signal intensity threshold was set at 6000. To minimize repeated sequencing, dynamic exclusion with duration of 90 s and mass tolerance of  $\pm 10$  ppm was utilized. MS/MS scans were performed in the Orbitrap. The AGC target was fixed at 1E5. For different sample inputs, different scan resolutions and injection times were used to maximize sensitivity (240k and 502 ms for blank control and ~10-cell samples; 120k and 246 ms for ~40-cell samples; 60k and 118 ms for ~140-cell samples).

#### Data Analysis:

**[0112]** All raw files were processed using Maxquant (version 1.5.3.30) for feature detection, database searching and protein/peptide quantification (Tyanova, S. et al 2016). MS/MS spectra were searched against the UniProtKB/Swiss-Prot human database (Downloaded in 12/29/2016 containing 20,129 reviewed sequences). N-terminal protein acetylation and methionine oxidation were selected as variable modifications. Carbamidomethylation of cysteine residues was set as a fixed modification. The peptide mass tolerances of the first search and main search (recalibrated) were < 20 and 4.5 ppm, respectively. The match tolerance, de novo tolerance, and deisotoping tolerance for MS/MS search were 20, 10, and 7 ppm, respectively. The minimum peptide length was 7 amino acids and maximum peptide mass was 4600 Da. The allowed missed cleavages for each peptide was 2. The second peptide search was activated to identify co-eluting and cofragmented peptides from one MS/MS spectrum. Both peptides and proteins were filtered with a maximum false discovery rate (FDR) of 0.01. The Match Between Runs feature, with a match window of 0.7 min and alignment window of 20 min, was activated to increase peptide/protein identification of low-cell-number samples. LFQ calculations were performed separately in each parameter group that containing similar cell loading. Both unique and razor peptides were selected for protein quantification. Requiring MS/MS for LFQ comparisons was not activated to increase the quantifiable proteins in low-cell-number samples. Other unmentioned parameters were the default settings of the Max-

quant software.

[0113] Perseus (Tyanova, S. et al. 2016) was used to perform data analysis and extraction. To identify the significantly changed proteins from a non-diabetic donor and a T1D donor, the datasets were filtered to contain 3 valid LFQ intensity values in at least one group. The missing values were imputed from normal distribution with a width of 0.3 and a down shift of 1.8. Two sample T-test with a minimal fold change of 2 and a FDR of 0.01 was performed for statistical analysis. The extracted data were further processed and visualized with OriginLab 2017. Global scaling normalization was achieved using scaling coefficients calculated as the ratio of peptide abundance to the median peptide abundance measured for each loading set. Coefficients of variation were calculated by dividing the standard deviation of normalized intensities by the mean intensity across the datasets of similar loading. The Violin plot was generated with an online tool (BoxPlotR, <http://shiny.chemgrid.org/boxplotr/>) (Spitzer, M. et al).

#### *nanoPOTS platform results and conclusions*

[0114] The nanoPOTS platform provided a robust, semi-automated nanodroplet-based proteomic processing system for handling extremely small biological samples down to as few as 10 cells with high processing efficiency and minimal sample loss. This capability opens up many potential biomedical applications from small cell populations and clinical specimens such as tissue sections for characterizing tissue or cellular heterogeneity. Reproducible quantitative proteome measurements with coverage of 2000-3,000 protein groups from as few as 10 mammalian cells or single human islet cross sections (~100 cells) from clinical specimens were demonstrated. While several previous efforts have pursued the analysis of <2000 cells, most of these methods lacked the robustness and reproducibility for biological applications because of the highly manual processes involved (Li, S. et al 2015, Chen, Q. et al 2015, Chen, W. et al. 2016, and Waanders, L. et al). The nanoPOTS platform not only provided unparalleled proteome coverage for analyzing 10-100 cells, but also offered a number of technical advantages for achieving a high degree of robustness and reproducibility for high throughput processing and quantitative measurements when coupled with LC-MS. First, the platform effectively addressed the bottleneck of sample losses during proteomics sample preparation by performing all of the multi-step reactions within a single nanodroplet of <200 nL volume, while all previous methods still suffer from a significant degree of protein/peptide losses during processing. Second, the nanodroplet processing mechanism allowed us to perform each reaction at optimal concentrations. For example, by preserving the 20-50:1 ratio (Vandermarlier, E. et al) of protein to protease within the nanodroplet, the digestion rate and efficiency is potentially increased by orders of magnitude relative to a standard-volume preparation for the same number of cells. Finally, in addition to label-free quantification, other stable isotopebased quantification methods are readily adaptable to the workflow.

[0115] Compared with other microfluidic platforms having closed microchannels and chambers (White, A. et al. 2011, and Zhu, Y. et al. 2010), the nanoPOTS has an open structure, which is inherently suitable for integration with upstream and downstream proteomic workflows, including sample isolation for processing and transfer for LC-MS analysis.

#### *Laser microdissected samples - Profiling of protein expression in thin sections of human islets*

[0116] To further explore potential applications involving characterization of substructures or molecular phenotyping of heterogeneous tissues such as human pancreas, the method was used to analyze cross-sections of individual human islets having a thickness of 10  $\mu\text{m}$  (FIG. 19) that were isolated by laser microdissection from clinical pancreatic specimens (FIG. 18A-18D). The islet equivalents (IEQ) were calculated to be from 0.06 to 0.17, corresponding to approximately 91 to 266 cells based on their volumes and a previous quantitative study (Zeiler, M. et al.) (Table 3).

Table 3. Calculation of cell number and islet equivalents with islet areas (Pisania, A. et al 2010).

	<i>Islet Area (<math>\mu\text{m}^2</math>)</i>	<i>Islet volume (<math>\mu\text{m}^3</math>)</i>	<i>Cell Number</i>	<i>Islet equivalents (IEQ)</i>
No1	30197	301973	266	0.17
No2	16200	162004	143	0.09
No3	21286	212862	188	0.12
No4	11133	111330	98	0.06
No5	14235	142354	125	0.08
No6	22428	224280	198	0.13
No7	10365	103654	91	0.06
No8	15186	151860	134	0.09
No9	21474	214738	189	0.12

[0117] An average of 2,511 and a total of 2,834 protein groups were identified for the nine single islet slices; 2,306

protein groups were quantifiable with valid intensities and >2 unique peptides in 5 out of 9 samples. The protein group identifications exceed those of previously reported single intact islets (Huang, E. et al 2016). Pairwise correlation analysis of protein LFQ intensity resulted in coefficients ranging from 0.93 to 0.97 (FIG. 20A and 20B), indicating a degree of islet heterogeneity. Gene Ontology analysis indicated that the proteome data provided coverage of cellular compartments similar to bulk analyses (FIG. 27), demonstrating the nanoPOTS avoid biases in protein extraction from different compartments. FIG. 21 further illustrated the coverage of a network of proteins involved in vesicular transport, including the SNARE and Coatamer complex (Clair, G. et al.), an important function for secreting islet cells. This initial study indicates nanoPOTS will specifically enable studies of single islet heterogeneity using clinical specimens to explore islet pathology of type 1 or type 2 diabetes (Pisania, A. et al.), and more broadly enable clinical analysis of many otherwise inaccessible samples.

**[0118]** Currently, there is no residue/adhesive-free method available to transfer samples from LMD to small-volume reactor vessel for effective sample preparation of small samples. This method is broadly applicable and transferrable in the fields of proteomics, metabolomics, lipidomics, peptidomics, genomics, transcriptomics, etc., as analysis of small samples isolated by LMD is limited by interference of the adhesive capture material and by the large volumes require by the process.

#### Example 2: nanoPOTS interface with FACS

**[0119]** Additionally, experiments showed that the nanoPOTS chip directly interfaced with fluorescence-activated cell sorting (FACS) for cell isolation. With the photolithography-based microfabrication technique, the nanodroplet array size and density can be easily scaled for increased preparation throughput.

**[0120]** While the current demonstrated limit is to analyze of as few as 10 cells, nanoPOTS represented a highly promising platform towards single mammalian cell proteomics with optimized processing volumes and further refinements to the LC-MS platform. To maximize the overall sensitivity of nanoPOTS for single cells, the total processing volume could be reduced to the lownanoliter range to further minimize sample loss. FACS or other cell isolation techniques should be used to isolate single cells into nanowells without the minimal exogenous contamination from, e.g., secreted proteins or lysed cells. NanoLC columns with narrower bore (Shen, Y. et al. 2004, and Shen, Y. 2003), and ESI emitter technology accommodating the lower resulting flow rates (Smit, R. et al.) could be employed to improve the detection sensitivity of the LC-MS system. Finally, in addition to single cell analysis, nanoPOTS should also provide a viable path towards tissue imaging at the proteome level by performing in-depth spatially resolved proteome measurements for specific cellular regions.

#### Example 3: nanoPOTS with LCM and capture liquid

**[0121]** Nanowells are prepopulated with DMSO droplets to serve as a sacrificial capture medium for small tissue samples in the nanoPOTS chip (**FIGS. 29A-29E**) as described below in detail.

**[0122]** Reagents and chemicals. Deionized water (18.2 MΩ) generated from a Barnstead Nanopure Infinity system (Los Angeles, CA) was used throughout. Dithiothreitol (DTT) and iodoacetamide (IAA) were from ThermoFisher Scientific (St. Louis, MO), and their working solutions were freshly prepared in 50 mM ammonium bicarbonate buffer before use. n-dodecyl-β-D-maltoside (DDM), Mayer's hematoxylin, eosin Y (alcoholic solution), Scott's Tap Water Substitute, DMSO were purchased from Sigma-Aldrich. Trypsin (MS grade) and Lys-C (MS grade) were from Promega (Madison, WI). Other unmentioned reagents were obtained from ThermoFisher.

**[0123]** Nanowell chip fabrication. The nanowell chip consisted of three parts including a nanowell-containing substrate, a spacer, and a cover plate. The nanowell substrate was fabricated with the similar procedures described previously. (Liu, Anal. Chem. 2017, 89(1), 822-829; Zhu, Anal. Chem. 2010, 82 (19), 8361-8366) Briefly, a glass slide (25 mm × 75 mm) with pre-coated chromium and photoresist (Telic company, Valencia, CA) was used as starting material. Standard photolithography and wet etching procedures were employed to generate an array of pedestals with a diameter of 1.2 mm, a height of 10 μm, and a spacing of 4.5 mm between adjacent pedestals on the slide. The exposed surfaces surrounding the pedestals were treated to be hydrophobic with 2% (v/v) heptadecafluoro-1,1,2,2-tetrahydrodecyl)dimethylchlorosilane (PFDS) (Sigma Aldrich) in 2,2,4-trimethylpentane. After removing the chromium layer, the pedestals maintained the hydrophilicity of untreated glass and served as nanoliter-scale wells for tissue collection and proteomic sample processing. The glass spacer was laser-machined (Coherent Inc., Santa Clara, CA) on a standard 1.2-mm-thick microscope slide. The machining process removed the center region of the slide, leaving a thin frame of ~5 mm in width. The machined slide was glued to the nanowell substrate using a silicone adhesive, and served as a spacer to limit the headspace of the nanowells after reversibly sealing to a cover plate to minimize evaporation during incubation steps, while prevent contact of the droplet reactors with the cover plate. The cover plate was produced by spin coating of a thin layer of Sylgard 184 and its curing reagent (10/1, v/v) (Dow Corning) at a spin speed of 500 rpm for 30 s followed by 3000 rpm for 5 min. The cover plate was baked at 70 °C for 10 hours to generate a ~30-μm-thick polydimethylsiloxane

(PDMS) layer.

**[0124]** Tissue preparation. Rats were anesthetized by intra-peritoneal injection of chloral hydrate. Rat brain was dissected and snap frozen in liquid nitrogen. The brains were stored at -80 °C until use. A cryostat (NX-70, Thermo Scientific, St. Louis, MO) was used to cut tissues to a thickness of 12 μm. The chuck and blade temperatures were set as -16 °C and -20 °C, respectively. The tissue sections were deposited on PEN membrane slides (Carl Zeiss Microscopy, Germany) and stored at -80 °C.

**[0125]** Before the hematoxylin and eosin (H&E) staining procedures, the tissue section was removed from the freezer or dry ice box and immediately immersed into 70% ethanol to fix proteins. The tissue was then rehydrated in deionized water for 30 s and stained in Mayer's hematoxylin solution for 1 min. Excess dye was rinsed with water and the tissue was blued in Scott's Tap Water Substitute for 15 s. Next, 70% ethanol was used to dehydrate the tissue and a 50% dilution of eosin Y solution (v/v in ethanol) was applied for 1-2 s by a quick dip. The tissue sample was further dehydrated by immersion twice in 95% ethanol for 30 s, twice in 100% ethanol for 30 s, and finally in xylene for 2 min. All the procedures were performed in a fume hood and the slide was blotted on absorbent paper between different solutions to minimize carry over. The processed tissue could be directly used for LCM or stored at -80 °C until use.

**[0126]** Laser capture microdissection. Unless mentioned otherwise, an array of DMSO droplets with a volume of 200 nL were deposited on nanowells using a nanoliter-dispensing robotic system (FIG. 29B). A PALM microbeam laser capture microdissection system (Carl Zeiss MicroImaging, Munich, Germany) was employed. The nanowell chip was fixed on a standard adapter for microscope slide (SlideCollector 48, Carl Zeiss MicroImaging) and then mounted on the robotic arm of the LCM system (FIG. 29C). The brain tissues were cut at an energy level of 42, and catapulted into DMSO droplet using the "CenterRoboLPC" function with an energy level of delta 15 and a focus level of delta 10. Tissue samples in the nanowell chip could be processed directly or stored at -20 °C.

**[0127]** NanoPOTS proteomic sample processing. Before processing, DMSO droplets were evaporated to dryness by keeping the nanowell chip in a vacuum desiccator for 10 to 15 min (FIG. 29E). Reagent dispensing was performed using the robotic system as described previously. (Zhu, Anal. Chem. 2013, 85 (14), 6723-6731; Zhu, Sci. Rep. 2015, 5, 9551; Zhu, Sci. Rep. 2014, 4, 5046) Briefly, 100 nL 1× PBS buffer containing 0.2% DDM surfactant and 5 mM DTT was added into each nanowell. The chip was incubated at 70 °C for 1 h for protein extraction and denaturation. Proteins were then alkylated by adding 50 nL of 30 mM IAA in 50 mM ammonium bicarbonate (ABC) in each reaction and then incubating for 40 min in the dark. A two-step digestion was performed at 37 °C with Lys-C and trypsin for 4 h and 8 h, respectively. Finally, the digested peptide samples were collected and stored in a fused silica capillary (4 cm long, 200 μm i.d., 360 μm o.d.). Each nanowell was washed twice with 200 nL, 0.1% formic acid aqueous buffer and the wash solution was also collected into the same capillary to maximize sample recovery. To prevent residual PEN membrane pieces be drawn into the collection capillary, the distance between the capillary distal end and the nanowell surface was kept at 100 μm during the sample aspiration process. The capillary was sealed with Parafilm at both ends and stored at -70 °C until analyzed.

**[0128]** NanoLC-MS/MS for protein identification. Samples in the collection capillary were desalted and concentrated on a solid phase extraction (SPE) column (75-μm-i.d. fused silica capillary packed with 3 μm, 300 Å pore size C18 particles, Phenomenex, Terrence, CA). Peptides were separated using a 60-cm-long, 30-μm-i.d. nanoLC column (3 μm, 300 Å pore size C18 particles, Phenomenex) with an integrated electrospray emitter (Self-Pack PicoFrit column, New Objective, Woburn, MA). A nanoUPLC pump (Dionex UltiMate NCP-3200RS, Thermo Scientific, Waltham, MI) was used to deliver mobile phase to the LC column. To obtain reproducible and smooth gradient profiles, a tee interface was used to split the LC flow rate from 300 nL/min to 50 nL/min for the 30-μm-i.d. LC column. A linear 100-min gradient starting from 8% buffer B (0.1% formic acid in acetonitrile; buffer A: 0.1% formic acid in water) to 22%, followed by a 15-min linear increase to 35% buffer B. The column was washed with 90% buffer B for 5 min and re-equilibrated with 2% buffer B for 20 min prior to the subsequent analysis.

**[0129]** Peptides were ionized at the nanospray source using a potential of 2 kV. An Orbitrap Fusion Lumos Tribrid MS (ThermoFisher) operated in data dependent mode to automatically switch between full scan MS and MS/MS acquisition with a cycle time of 2 s. The ion transfer capillary was heated to 250 °C to accelerate desolvation, and the S lens was set at 30. Full-scan MS spectra ( $m/z$  375-1600) were acquired in the Orbitrap analyzer with 120,000 resolution ( $m/z$  200), and AGC target of  $3 \times 10^6$ , and a maximum ion accumulation time of 246 ms. Precursor ions with charges from +2 to +7 were isolated with an  $m/z$  window of 2 and were sequentially fragmented by high energy dissociation (HCD) with a collision energy of 30%. The AGC target was set at  $1 \times 10^5$ . MS/MS scan spectra were acquired in the Orbitrap with an ion accumulation time of 502 ms and resolution of 240,000 for 50-μm-diameter tissue sample, an ion accumulation time of 246 ms and 120,000 resolution for 100-μm-diameter tissue sample, or an ion accumulation time of 118 ms and 60,000 resolution for 200-μm-diameter tissue samples, respectively.

**[0130]** Data Analysis. Raw data were analyzed by MaxQuant 1.5.3.30 as previously described. Briefly, Andromeda engine was used to search MS/MS spectra against a UniProtKB/Swiss-Prot mouse database containing 16,935 reviewed entries. Carbamidomethylation was set as a fixed modification, and n-terminal protein acetylation and methionine oxidation were set as variable modifications. Recalibrated MS/MS spectra were matched with a tolerance of 5 ppm on

precursor mass and 20 ppm on fragment mass. The minimum peptide length was set at 6 amino acids, and maximum peptide mass was 4600 Da. Two missed cleavages were allowed for each peptide. A false discovery rate (FDR) of 1% was applied for both peptide and protein filtering. For the spatially resolved study of brain tissue samples, Match Between Runs (MBR) was activated to enhance identification sensitivity. The time windows for feature alignment and match were 20 min, and 0.7 min, respectively. Label-free relative protein quantification (LFQ) was performed in each parameter group containing tissue samples of similar size.

**[0131]** Contamination and reverse identification was filtered with Perseus (version 1.5.6.0). For relative quantification, the LFQ intensities were transformed with log2 function, and then filtered to contain > 70% valid values in at least one group. The missing values were imputed by normal distribution in each column with a width of 0.3 and a down shift of 1.8. To identify significant differences, ANOVA multiple sample test with permutation-based FDR control approach was used. P-value <0.01, q-value <0.05, and fold change >4 ( $S_0 = 2$ ) were required to obtain significant proteins. The results were exported to a table and visualized with OriginPro 2017 and an online tool powered by R language.

**[0132]** The capture efficiency with square tissues having side lengths of 20  $\mu\text{m}$ , 50  $\mu\text{m}$ , 100  $\mu\text{m}$ , and 200  $\mu\text{m}$  using a 12- $\mu\text{m}$ -thick breast cancer tissue section from a previous study was evaluated. For smaller tissue samples with square side lengths from 20  $\mu\text{m}$  to 100  $\mu\text{m}$ , a total of 75 cuts were collected into three droplets for each size. For the largest tissue samples (200  $\mu\text{m}$ ), a total of 27 cuts were collected. The "CenterRoboLPC" function, in which the catapult laser pulse was applied at the centroid of pre-cut tissue piece, was used instead of commonly-used "RoboLPC". The "CenterRoboLPC" function provided better control on the catapult trajectory of tissue pieces from slide to DMSO droplets. Under the optimized condition, the capture efficiencies ranged from 92% to 97% for smaller tissue samples (20  $\mu\text{m}$  to 100  $\mu\text{m}$ ), indicating the majority of LCM tissues can be collected (**FIG. 30B**). When tissue diameters were equal to or larger than 200  $\mu\text{m}$ , all were successfully collected. With the increase of tissue sizes, the dissection time increased from 6 s to 15 s for each tissue sample. The high-speed dissection and high capture efficiencies, along with batch sample processing, should enable many applications requiring high-throughput proteomic studies such as large-scale mapping of heterogeneous tissues. It should also be noted that tissue pieces with a diameter of 20  $\mu\text{m}$  correspond to single cells in most of mammalian tissues, demonstrating the potential of the present approach for single-cell isolation and analysis.

**[0133]** Proteomic analysis of LCM isolated rat brain tissues. To determine whether DMSO adversely affected tissue analysis, rat cortex tissue samples collected with DMSO droplets were analyzed, and compared with that obtained using manual transfer without DMSO. Surprisingly, a 71% and 69% increase in average and total unique peptide identifications was observed, respectively, resulting in the corresponding 44% and 29% increase in protein identifications, when DMSO was used for tissue collection (**FIG. 31A**). A Venn diagram of total protein identifications indicates that most of the proteins obtained from DMSO-free samples were included in that of DMSO-collected samples (**FIG. 31B**). This demonstrates that the use of DMSO droplets did not generate any negative effects on the proteomic analysis. On the contrary, proteome coverage significantly increased for small tissue samples. A possible explanation for this result is that protein extraction efficiency was improved after hydrophobic lipids were removed by DMSO in the brain tissue. Protein extraction from tissue samples was found to be more challenging than for cultured cells, especially for tissue containing high lipid content such as brain. Various approaches have been developed to address this challenge by employing strong detergents or organic solvent in the extraction buffer. As a type of organic solvent, DMSO is expected to have high solubility for most lipids, and thus could dissolve them prior to protein extraction. Compared with commonly used detergent approaches, sample losses in detergent removing steps including buffer exchange and spin columns was avoided using the inventive approach described herein. These merits of DMSO have thus provided an added benefit in the workflow of spatially-resolved proteomic analysis.

**[0134]** The sensitivity of the LCM-DMSO-nanoPOTS system on proteomic analysis of small tissue samples was tested. Rat cortex tissue with diameters of 50  $\mu\text{m}$ , 100  $\mu\text{m}$ , and 200  $\mu\text{m}$  were used as model samples. Based on hematoxylin staining of cell nuclei provided by Allen brain atlas project, the corresponding cell numbers were ~3-10, 20-40, and 40-100, for the different tissue diameters, respectively. **FIGS. 31D** and **31E** show the linear increase of unique peptide and protein identifications with tissue size. As expected, nearly all peptides and proteins identified in the smaller tissues were also identified in larger tissues (**FIG. 31D**), demonstrating analytical sensitivity dominated the proteome coverage. The present system is capable of identifying an average of  $159 \pm 40$ ,  $857 \pm 104$ , and  $1717 \pm 33$  protein groups ( $n=3$ ) from cortex tissues with diameters of 50  $\mu\text{m}$ , 100  $\mu\text{m}$ , and 200  $\mu\text{m}$ , respectively. Compared with previous spatially-resolved proteomic studies, in which at least millimeter-sized tissues were required to obtain a depth >1000 proteins, the LCM-DMSO-nanoPOTS system provided >25 times better spatial resolution with higher proteome coverage.

**[0135]** The 1918 total proteins identified from 200- $\mu\text{m}$ -diameter cortex tissues were submitted for Gene Ontology Cellular Component (GOCC) analysis. As shown in **FIG. 31G**, we observed a high percentage (56%) of membrane proteins and half of them (28%) were localized in plasma membrane, although no specific sample preparation procedures were used for membrane proteins. 10% synapse proteins and 7% axon proteins (not shown in **FIG. 31G**), which are vital for brain function, were also observed. In brain, the major neurotransmitters are glutamate and GABA, which play excitatory and inhibitory functions, respectively. In the plasma protein category, we identified three types of GABA receptors (GABRA1, GABRA2, GABRB1, GABRB2, GABRG2), and a large family of glutamate receptors

including DRIA1, DRIA2, DRIA3, DRIA4, GRM2, GRM3, GRM5, GPR158, GRIK3, GRIN1, GRIN2a, and GRIN2b.

**[0136]** Quantitative, spatially-resolved proteomic study of rat brain tissues. The performance of the LCM-DMSO-nanoPOTS system was evaluated for quantitative and spatially-resolved proteomic studies, we dissected and analyzed three different rat brain regions (cerebral cortex (CTX), corpus callosum (CC), and caudoputamen (CP)) from a 12- $\mu$ m-thick coronal section (**FIGS. 32A-32C**). Tissue samples were dissected with a diameter of 100  $\mu$ m, corresponding to an area of  $\sim 0.008$  mm<sup>2</sup>. The spatial distances (center to center) were from 116  $\mu$ m to 716  $\mu$ m between the same regions, and from 424  $\mu$ m to 1,727  $\mu$ m between different regions (**FIG. 32A**), showing the high spatial resolution of the present measurement. For each region, six samples were processed and four of them were submitted for LC-MS analysis (**FIG. 32B**).

**[0137]** To increase the quantifiable proteins, the Match Between Runs (MBR) algorithm of Maxquant was used, wherein the peptides were identified based on accurate intact masses and LC retention times (AMTs). A total 1896 protein groups were identified and 1393 (73.5%) were common across all the three brain regions. After stringent filtering for valid log<sub>2</sub>-transformed LFQ values, 1,003 protein groups were quantifiable. A high correlation with Pearson's correlation coefficients from 0.97 to 0.99 was observed between biological replicates of the same tissue regions, demonstrating excellent technical and biological reproducibility of the present system for quantification (**FIG. 32C**). Between different tissue regions, CTX and CP shows lower in correlation coefficients from 0.94 to 0.97, while CC has lowest correlations (from 0.83 to 0.91) with the other two regions. Such differences are also indicated in the morphology of the brain tissue (**FIG. 32A**).

**[0138]** The LCM-DMSO-nanoPOTS system was tested to see if it could be applied to distinguish different tissue types. Unsupervised principal component analysis (PCA) was used to process the LFQ intensity data from the 12 tissue samples. As shown in **FIG. 33A**, the three tissue regions were segregated based on component 1 and component 2, which accounted for 65.5% and 15.6%, respectively. All four biological replicates were well clustered within the corresponding tissue region without overlap with other regions, suggesting the present system can efficiently distinguish tissue types based on their protein expressions.

**[0139]** To identify significant differences in protein expression among the three tissue regions, a multiple sample ANOVA test was employed with a permutation-based FDR algorithm, which is embedded in Perseus data analysis platform. Using a difference (S0) of 2, p-value of 0.01, and a FDR level of 0.05, 233 out of total 1003 quantifiable protein groups were identified to have significant differences. The most abundant proteins, such as Tuba1b, Tubb2a, Actb, Sptan1, Cltc, and Atp5b, were found to have no difference in LFQ intensity, which agrees well with previous report. For the 233 significant proteins, 32, 27, 43 proteins groups enriched in CTX, CC, and CP regions with fold change >2 over their mean values were observed, respectively. To visualize the difference, we used unsupervised hierarchical clustering analysis (HCA) of the significant proteins (**FIG. 33B**). Similar to PCA plot, each four replicates from the same regions were clustered together. In addition, each region has distinct hot spots in protein abundance relative to other regions, indicating different biological functions existed in these regions.

**[0140]** The results described herein demonstrate that the LCM- capture liquid-nanoPOTS platform significantly advances spatially-resolved proteomics by improving the resolution and increasing the sensitivity. The use of DMSO droplets not only served to efficiently capture dissected tissue pieces as small as 20- $\mu$ m diameter (single-cell scale) into nanowells, but also significantly improved the proteome coverage. The whole workflow can be fully automated without manual transfer, and thus sample loss and protein contamination is minimized. This platform may play an important role in proteomic analyses and may be applied to various fields including biomedical research, clinical diagnosis, microbial community, and plant science. Finally, the LCM- capture liquid-nanoPOTS platform should be readily extended to other omics studies requiring tissue isolation and nanoscale processing, such as transcriptomics, lipidomics, and metabolomics.

**[0141]** Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition or concentration range, all intermediate ranges and sub-ranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. As used herein, ranges specifically include the values provided as endpoint values of the range. For example, a range of 1 to 100 specifically includes the end point values of 1 and 100. It will be understood that any sub-ranges or individual values in a range or sub-range that are included in the description herein can be excluded from the claims herein.

1. Achim, K. et al. High-throughput spatial mapping of single-cell RNA-seq data to tissue of origin. *Nat. Biotechnol.* 33, 503-509 (2015).

2. Jaitin, D. A. et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. *Science* 343, 776-779 (2014).

3. Shapiro, E., Biezuner, T. & Linnarsson, S. Single-cell sequencing-based technologies will revolutionize whole-organism science. *Nat. Rev. Genet.* 14, 618-630 (2013).



4. Bendall, S. C. et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. *Science* 332, 687-696 (2011).
5. Smith, R. D., Shen, Y. & Tang, K. Ultrasensitive and quantitative analyses from combined separations-mass spectrometry for the characterization of proteomes. *Acc. Chem. Res.* 37, 269-278 (2004).
6. Shen, Y. et al. Ultrasensitive proteomics using high-efficiency on-line micro-spe-nanolc-nanoesi ms and ms/ms. *Anal. Chem.* 76, 144-154 (2004).
10. 7. Sun, L. et al. Ultrasensitive and fast bottom-up analysis of femtogram amounts of complex proteome digests. *Angew. Chemie - Int. Ed.* 52, 13661-13664 (2013).
8. Kelly, R. T., Tolmachev, A. V, Page, J. S., Tang, K. & Smith, R. D. The ion funnel: Theory, implementations, and applications. *Mass Spectrom. Rev.* 29, 294-312 (2010).
15. 9. Li, S. et al. An integrated platform for isolation, processing, and mass spectrometry-based proteomic profiling of rare cells in whole blood. *Mol. Cell. Proteomics* 14, 1672-1683 (2015).
20. 10. Sun, X., Kelly, R. T., Tang, K. & Smith, R. D. Ultrasensitive nanoelectrospray ionization-mass spectrometry using poly(dimethylsiloxane) microchips with monolithically integrated emitters. *Analyst* 135, 2296-2302 (2010).
11. Wang, H. et al. Development and evaluation of a micro- and nanoscale proteomic sample preparation method. *J. Proteome Res.* 4, 2397-403 (2005).
25. 12. Wisniewski, J. R., Ostasiewicz, P. & Mann, M. High recovery FASP applied to the proteomic analysis of micro-dissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. *J. Proteome Res.* 10, 3040-3049 (2011).
30. 13. Chen, Q., Yan, G., Gao, M. & Zhang, X. Ultrasensitive proteome profiling for 100 living cells by direct cell injection, online digestion and nano-lc-ms/ms analysis. *Anal. Chem.* 87, 6674-6680 (2015).
14. Chen, W. et al. Simple and integrated spintip-based technology applied for deep proteome profiling. *Anal. Chem.* 88, 4864-4871 (2016).
35. 15. Waanders, L. F. et al. Quantitative proteomic analysis of single pancreatic islets. *Proc.Natl.AcadSci U.S.A* 106, 18902-18907 (2009).
16. Huang, E. L. et al. Snapp: Simplified nanoproteomics platform for reproducible global proteomic analysis of nanogram protein quantities. *Endocrinology* 157, 1307-1314 (2016).
40. 17. Wang, N., Xu, M., Wang, P. & Li, L. Development of mass spectrometry-based shotgun method for proteome analysis of 500 to 5000 cancer cells. *Anal. Chem.* 82, 2262-2271 (2010).
45. 18. Lombard-Banek, C., Moody, S. A. & Nemes, P. Single-cell mass spectrometry for discovery proteomics: quantifying translational cell heterogeneity in the 16-cell frog (*xenopus*) embryo. *Angew. Chemie - Int. Ed.* 55, 2454-2458 (2016).
19. Sun, L. et al. Single cell proteomics using frog (*Xenopus laevis*) blastomeres isolated from early stage embryos, which form a geometric progression in protein content. *Anal. Chem.* 88, 6653-6657 (2016).
50. 20. Wisniewski, J. R., Hein, M. Y., Cox, J. & Mann, M. A 'proteomic ruler' for protein copy number and concentration estimation without spike-in standards. *Mol. Cell. Proteomics* 13, 3497-506 (2014).
21. Goebel-Stengel, M., Stengel, A., Taché, Y. & Reeve, J. R. The importance of using the optimal plasticware and glassware in studies involving peptides. *Anal. Biochem.* 414, 38-46 (2011).
55. 22. Zhu, Y., Zhang, Y.-X., Cai, L.-F. & Fang, Q. Sequential operation droplet array: an automated microfluidic platform for picoliter-scale liquid handling, analysis, and screening. *Anal. Chem.* 85, 6723-6731 (2013).

23. Vandermarliere, E., Mueller, M. & Martens, L. Getting intimate with trypsin, the leading protease in proteomics. *Mass Spectrom. Rev.* 32, 453-465 (2013).
24. Shen, Y. et al. Coupling to 15 - 150-  $\mu$  m-i . d . column liquid chromatography for proteomic analysis. *Anal. Chem.* 75, 3596-3605 (2003).
25. Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.* 11, 2301-2319 (2016).
26. Volpe, P. & Erememko-Volpe, T. Quantitative studies on cell proteins in suspension cultures. *Eur. J. Biochem.* 12, 195-200 (1970).
27. Zeiler, M., Straube, W. L., Lundberg, E., Uhlen, M. & Mann, M. A Protein Epitope Signature Tag (PrEST) library allows SILAC-based absolute quantification and multiplexed determination of protein copy numbers in cell lines. *Mol. Cell. Proteomics* 11, O111.009613 (2012).
28. Clair, G. et al. Spatially-resolved proteomics: rapid quantitative analysis of laser capture microdissected alveolar tissue samples. *Sci. Rep.* 6, 39223 (2016).
29. Pisania, A. et al. Quantitative analysis of cell composition and purity of human pancreatic islet preparations. *Lab. Investig.* 90, 1661-1675 (2010). [[SUPPORTING #7]]
30. Rodriguez-calvo, T. et al. Heterogeneity and lobularity of pancreatic pathology in type 1 diabetes during the prediabetic phase. *J. Histochem. Cytochem.* 63, 626-636 (2015).
31. Richardson, S. J. et al. Islet cell hyperexpression of HLA class I antigens : a defining feature in type 1 diabetes. *Diabetologia* 59, 2448-2458 (2016).
32. Rowe, P. A., Campbell-Thompson, M. L., Schatz, D. A. & Atkinson, M. A. The pancreas in human type 1 diabetes. *Semin. Immunopathol.* 33, 29-43 (2011).
33. White, A. K. et al. High-throughput microfluidic single-cell RT-qPCR. *Proc. Natl. Acad. Sci. U. S. A.* 108, 13999-14004 (2011).
34. Zhu, Y. & Fang, Q. Integrated droplet analysis system with electrospray ionization-mass spectrometry using a hydrophilic tongue-based droplet extraction interface. *Anal. Chem.* 82, 8361-8366 (2010).
35. Zhu, Y. et al. Printing 2-dimentional droplet array for single-cell reverse transcription quantitative per assay with a microfluidic robot. *Sci. Rep.* 5, 9551 (2015).
36. Zhu, Y. et al. Nanoliter-scale protein crystallization and screening with a microfluidic droplet robot. *Sci. Rep.* 4, 5046 (2014).
37. Schneider, C. a, Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* 9, 671-675 (2012).
38. Yu, Y. Q., Gilar, M., Lee, P. J., Bouvier, E. S. P. & Gebler, J. C. Enzyme-friendly, mass spectrometry-compatible surfactant for in-solution enzymatic digestion of proteins. *Anal. Chem.* 75, 6023-6028 (2003).
39. Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* 13, 731-740 (2016).
40. Spitzer, M., Wildenhain, J., Rappsilber, J. & Tyers, M. BoxPlotR: a web tool for generation of box plots. *Nat. Methods* 11, 121-2 (2014).

**Claims**

1. A method for preparing a biological sample (604), comprising the steps of

obtaining a biological tissue sample via tissue laser-capture microdissection;  
 providing a platform (100, 200) including at least one reactor vessel (400, 410, 420) having one or more hydrophilic surfaces (404) configured for containment of the biological tissue sample, wherein the hydrophilic surfaces have a non-zero, total surface area less than 25 mm<sup>2</sup>;  
 introducing a capture liquid (603) into or onto the at least one reactor vessel, wherein the capture liquid has a vapor pressure of less than or equal to 0.8 mbar at room temperature;  
 transferring a first volume of the biological tissue sample to the at least one reactor vessel that includes the capture liquid, wherein the first volume is a non-zero amount less than 1000 nL;  
 fully or partly evaporating the capture liquid after transferring the first volume of the biological tissue sample to the at least one reactor vessel; subsequently  
 processing the biological tissue sample in the at least one reactor vessel to yield a processed sample, and collecting a second volume of the processed sample.

2. The method of claim 1, wherein the biological tissue sample is from a biopsy.

3. The method of claim 1 or claim 2, wherein the second volume is a fraction of the first volume ranging from about 10 to about 100%.

4. The method of any one of claims 1 to 3, wherein the biological sample comprises a non-zero amount of cells less than 5000 cells.

5. The method of any one of claims 1 to 4, wherein the biological sample comprises a non-zero amount of cells less than 100 cells.

6. The method of any one of claims 1 to 5, further comprising analyzing the collected second volume of the processed biological sample, wherein the analyzing step is configured to identify at least one unique species within the processed biological sample.

7. The method of any one of claims 1 to 6, wherein processing the biological tissue sample comprises at least one of cell lysis, analyte extraction and solubilization, denaturation, reduction, alkylation, chemical and enzymatic reactions, concentration, and incubation.

8. The method of any one of claims 1 to 7, wherein the biological tissue sample obtained via the laser-capture microdissection has dimensions less than about 1 mm.

9. The method of any one of claims 1 to 8, wherein the capture liquid is dimethyl sulfoxide.

10. The method of any one of claims 1 to 9, wherein the capture liquid is present in an amount of at least 1 nL to 1000 nL in each of the at least one reactor vessel.

11. The method of any one of claims 1 to 10, wherein the biological tissue sample is brain tissue.

12. The method of claim 1, wherein the capture liquid extracts at least one analyte of interest from the biological tissue sample.

**Patentansprüche**

1. Verfahren zum Vorbereiten einer biologischen Probe (604), umfassend die folgenden Schritte:

Erhalten einer biologischen Gewebeprobe durch Gewebe-Laser-Capture-Mikrodissektion;  
 Bereitstellen einer Plattform (100, 200), die mindestens ein Reaktorgefäß beinhaltet, das eine oder mehrere hydrophile Oberflächen (400, 410, 420) aufweist, die zum Enthalten der biologischen Gewebeprobe ausgelegt sind, wobei die hydrophilen Oberflächen (404) eine von Null verschiedene Gesamtoberfläche kleiner 25 mm<sup>2</sup>

aufweisen;

Einführen einer Auffangflüssigkeit (603) in oder auf das mindestens eine Reaktorgefäß, wobei die Auffangflüssigkeit bei Raumtemperatur einen Dampfdruck von kleiner oder gleich 0,8 mbar aufweist;

Übertragen eines ersten Volumens der biologischen Gewebeprobe in das mindestens eine Reaktorgefäß, das die Auffangflüssigkeit beinhaltet, wobei das erste Volumen eine von Null verschiedene Menge kleiner 1000 nL ist; vollständiges oder partielles Verdampfenlassen der Auffangflüssigkeit nach dem Übertragen des ersten Volumens der biologischen Gewebeprobe in das mindestens eine Reaktorgefäß; anschließend

Verarbeiten der biologischen Gewebeprobe in dem mindestens einen Reaktorgefäß, um eine verarbeitete Probe zu erzielen, und

Sammeln eines zweiten Volumens der verarbeiteten Probe.

2. Verfahren nach Anspruch 1, wobei die biologische Gewebeprobe aus einer Biopsie stammt.

3. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das zweite Volumen ein Bruchteil des ersten Volumens im Bereich von etwa 10 bis etwa 100 % ist.

4. Verfahren nach einem der Ansprüche 1 bis 3, wobei die biologische Probe eine von Null verschiedene Menge an Zellen kleiner 5000 Zellen umfasst.

5. Verfahren nach einem der Ansprüche 1 bis 4, wobei die biologische Probe eine von Null verschiedene Menge an Zellen kleiner 100 Zellen umfasst.

6. Verfahren nach einem der Ansprüche 1 bis 5, ferner umfassend Analysieren des gesammelten zweiten Volumens der verarbeiteten biologischen Probe, wobei der Analyseschritt dazu ausgelegt ist, mindestens eine einzigartige Art innerhalb der verarbeiteten biologischen Probe zu identifizieren.

7. Verfahren nach einem der Ansprüche 1 bis 6, wobei das Vorbereiten der biologischen Gewebeprobe mindestens eines von Zelllyse, Analytextraktion und Solubilisierung, Denaturierung, Reduktion, Alkylierung, chemischen und enzymatischen Reaktionen, Konzentration und Inkubation umfasst.

8. Verfahren nach einem der Ansprüche 1 bis 7, wobei die biologische Gewebeprobe, die durch die ein Laser-Capture-Mikrodissektion erhalten wurde, Abmessungen kleiner etwa 1 mm aufweist.

9. Verfahren nach einem der Ansprüche 1 bis 8, wobei die Auffangflüssigkeit Dimethylsulfoxid ist.

10. Verfahren nach einem der Ansprüche 1 bis 9, wobei die Auffangflüssigkeit in einer Menge von mindestens 1 nL bis 1000 nL in jedem von dem mindestens einen Reaktorgefäß vorhanden ist.

11. Verfahren nach einem der Ansprüche 1 bis 10, wobei die biologische Gewebeprobe Gehirngewebe ist.

12. Verfahren nach Anspruch 1, wobei die Auffangflüssigkeit mindestens einen interessierenden Analyten aus der biologischen Gewebeprobe extrahiert.

## Revendications

1. Méthode de préparation d'un échantillon biologique (604), comprenant les étapes de :

obtention d'un échantillon de tissu biologique par microdissection par capture laser de tissu ;

fourniture d'une plateforme (100, 200) comprenant au moins une cuve de réacteur (400, 410, 420) comportant une ou plusieurs surfaces hydrophiles (404) conçues pour le confinement de l'échantillon de tissu biologique, lesdites surfaces hydrophiles comportant une surface spécifique totale non nulle inférieure à 25 mm<sup>2</sup> ;

introduction d'un liquide de capture (603) dans et sur ladite au moins une cuve de réacteur, ledit liquide de capture comportant une pression de vapeur inférieure ou égale à 0,8 mbar à température ambiante ;

transfert d'un premier volume de l'échantillon de tissu biologique vers ladite au moins une cuve de réacteur qui comprend le liquide de capture, ledit premier volume étant une quantité non nulle inférieure à 1000 nL ;

évaporation partielle ou complète du liquide de capture après transfert du premier volume de l'échantillon de tissu biologique vers ladite au moins une cuve de réacteur ; par la suite

traitement de l'échantillon de tissu biologique dans ladite au moins une cuve de réacteur pour produire un échantillon traité, et collecte d'un second volume de l'échantillon traité.

- 5     **2.** Méthode selon la revendication 1, ledit échantillon de tissu biologique provenant d'une biopsie.
- 3.** Méthode selon la revendication 1 ou la revendication 2, ledit second volume étant une fraction du premier volume allant d'environ 10 à environ 100 %.
- 10    **4.** Méthode selon l'une quelconque des revendications 1 à 3, ledit échantillon biologique comprenant une quantité non nulle de cellules inférieure à 5000 cellules.
- 5.** Méthode selon l'une quelconque des revendications 1 à 4, ledit échantillon biologique comprenant une quantité non nulle de cellules inférieure à 100 cellules.
- 15    **6.** Méthode selon l'une quelconque des revendications 1 à 5, comprenant en outre l'analyse du second volume recueilli de l'échantillon biologique traité, ladite étape d'analyse étant conçue pour identifier au moins une espèce unique au sein de l'échantillon traité.
- 20    **7.** Méthode selon l'une quelconque des revendications 1 à 6, ledit traitement de l'échantillon de tissu biologique comprenant au moins un traitement parmi une lyse cellulaire, une extraction et une solubilisation d'analytes, une dénaturation, une réduction, une alkylation, les réactions chimiques et enzymatiques, une concentration et une incubation.
- 25    **8.** Méthode selon l'une quelconque des revendications 1 à 7, ledit échantillon de tissu biologique obtenu par microdissection par capture laser de tissu comportant des dimensions inférieures à environ 1 mm.
- 9.** Méthode selon l'une quelconque des revendications 1 à 8, ledit liquide de capture étant le sulfoxyde de diméthyle.
- 30    **10.** Méthode selon l'une quelconque des revendications 1 à 9, ledit liquide de capture étant présent en une quantité d'au moins 1 nL à 1000 nL dans chacune de ladite au moins une cuve de réacteur.
- 11.** Méthode selon l'une quelconque des revendications 1 à 10, ledit échantillon de tissu biologique étant du tissu cérébral.
- 35    **12.** Méthode selon la revendication 1, ledit liquide de capture extrayant au moins un analyte d'intérêt à partir de l'échantillon de tissu biologique.

40

45

50

55




FIG. 1





FIG. 2








FIG. 4A






FIG. 4B





**FIG. 6**




FIG. 7







FIG. 8



**FIG. 9**



**FIG. 10**



**FIG. 11A**





FIG. 11C


FIG. 11B




**FIG. 13A**




**FIG. 13B**




**FIG. 13C**




**FIG. 12A**



**FIG. 12B**



**FIG. 12C**






FIG. 14A

FIG. 14B




FIG. 15

FIG. 16B






FIG. 16A




**FIG. 17A**





**FIG. 17B**

**FIG. 17C**



**FIG. 17D**





**FIG. 19**





FIG. 20A





**FIG. 20B**




FIG. 21







FIG. 22




**FIG. 23A**




**FIG. 23B**




**FIG. 23C**




**FIG. 23D**




**FIG. 24A**




**FIG. 24B**




**FIG. 24C**



**FIG. 25A**




**FIG. 25B**




**FIG. 25C**






**FIG. 26A**



**FIG. 26B**



**FIG. 26C**





FIG. 27



**FIG. 28**

FIG. 29A





FIG. 29B



**FIG. 29C**




FIG. 29D







FIG. 29E






FIG. 30A




FIG. 30B

FIG. 31A





FIG. 31B



**FIG. 31C**




FIG. 31D





FIG. 31E



**FIG. 31F**







FIG. 31G



**FIG. 32A**



**FIG. 32B**




FIG. 32C




FIG. 33A




FIG. 33B




FIG. 34A





FIG. 34B



## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 2017144886 A1 [0004]

## Non-patent literature cited in the description

- LIU. *Anal. Chem.*, 2017, vol. 89 (1), 822-829 [0123]
- ZHU. *Anal. Chem.*, 2010, vol. 82 (19), 8361-8366 [0123]
- ZHU. *Anal. Chem.*, 2013, vol. 85 (14), 6723-6731 [0127]
- ZHU. *Sci. Rep.*, 2015, vol. 5, 9551 [0127]
- ZHU. *Sci. Rep.*, 2014, vol. 4, 5046 [0127]
- ACHIM, K. et al. High-throughput spatial mapping of single-cell RNA-seq data to tissue of origin. *Nat. Biotechnol.*, 2015, vol. 33, 503-509 [0141]
- JAITIN, D. A. et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. *Science*, 2014, vol. 343, 776-779 [0141]
- SHAPIRO, E. ; BIEZUNER, T. ; LINNARSSON, S. Single-cell sequencing-based technologies will revolutionize whole-organism science. *Nat. Rev. Genet.*, 2013, vol. 14, 618-630 [0141]
- BENDALL, S. C. et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. *Science*, 2011, vol. 332, 687-696 [0141]
- SMITH, R. D. ; SHEN, Y. ; TANG, K. Ultrasensitive and quantitative analyses from combined separations-mass spectrometry for the characterization of proteomes. *Acc. Chem. Res.*, 2004, vol. 37, 269-278 [0141]
- SHEN, Y. et al. Ultrasensitive proteomics using high-efficiency on-line micro-spe-nanolc-nanoESI ms and ms/ms. *Anal. Chem.*, 2004, vol. 76, 144-154 [0141]
- SUN, L. et al. Ultrasensitive and fast bottom-up analysis of femtogram amounts of complex proteome digests. *Angew. Chemie - Int. Ed.*, 2013, vol. 52, 13661-13664 [0141]
- KELLY, R. T. ; TOLMACHEV, A. V. ; PAGE, J. S. ; TANG, K. ; SMITH, R. D. The ion funnel: Theory, implementations, and applications. *Mass Spectrom. Rev.*, 2010, vol. 29, 294-312 [0141]
- LI, S. et al. An integrated platform for isolation, processing, and mass spectrometry-based proteomic profiling of rare cells in whole blood. *Mol. Cell. Proteomics*, 2015, vol. 14, 1672-1683 [0141]
- SUN, X. ; KELLY, R. T. ; TANG, K. ; SMITH, R. D. Ultrasensitive nanoelectrospray ionization-mass spectrometry using poly(dimethylsiloxane) microchips with monolithically integrated emitters. *Analyst*, 2010, vol. 135, 2296-2302 [0141]
- WANG, H. et al. Development and evaluation of a micro- and nanoscale proteomic sample preparation method. *J. Proteome Res.*, 2005, vol. 4, 2397-403 [0141]
- CHEN, Q. ; YAN, G. ; GAO, M. ; ZHANG, X. Ultra-sensitive proteome profiling for 100 living cells by direct cell injection, online digestion and nano-LC-MS/MS analysis. *Anal. Chem.*, 2015, vol. 87, 6674-6680 [0141]
- CHEN, W. et al. Simple and integrated spintip-based technology applied for deep proteome profiling. *Anal. Chem.*, 2016, vol. 88, 4864-4871 [0141]
- WAANDERS, L. F. et al. Quantitative proteomic analysis of single pancreatic islets. *Proc. Natl. Acad. Sci. U.S.A.*, 2009, vol. 106, 18902-18907 [0141]
- HUANG, E. L. et al. Snapp: Simplified nanoproteomics platform for reproducible global proteomic analysis of nanogram protein quantities. *Endocrinology*, 2016, vol. 157, 1307-1314 [0141]
- WANG, N. ; XU, M. ; WANG, P. ; LI, L. Development of mass spectrometry-based shotgun method for proteome analysis of 500 to 5000 cancer cells. *Anal. Chem.*, 2010, vol. 82, 2262-2271 [0141]
- LOMBARD-BANEK, C. ; MOODY, S. A. ; NEMES, P. Single-cell mass spectrometry for discovery proteomics: quantifying translational cell heterogeneity in the 16-cell frog (*Xenopus*) embryo. *Angew. Chemie - Int. Ed.*, 2016, vol. 55, 2454-2458 [0141]
- SUN, L. et al. Single cell proteomics using frog (*Xenopus laevis*) blastomeres isolated from early stage embryos, which form a geometric progression in protein content. *Anal. Chem.*, 2016, vol. 88, 6653-6657 [0141]
- GOEBEL-STENGEL, M. ; STENGEL, A. ; TACHÉ, Y. ; REEVE, J. R. The importance of using the optimal plasticware and glassware in studies involving peptides. *Anal. Biochem.*, 2011, vol. 414, 38-46 [0141]



- **ZHU, Y. ; ZHANG, Y.-X. ; CAI, L.-F. ; FANG, Q.** Sequential operation droplet array: an automated microfluidic platform for picoliter-scale liquid handling, analysis, and screening. *Anal. Chem.*, 2013, vol. 85, 6723-6731 [0141]
- **VANDERMARLIERE, E. ; MUELLER, M. ; MARTENS, L.** Getting intimate with trypsin, the leading protease in proteomics. *Mass Spectrom. Rev.*, 2013, vol. 32, 453-465 [0141]
- **SHEN, Y. et al.** Coupling to 15- 150- $\mu$ m-i . d . column liquid chromatography for proteomic analysis. *Anal. Chem.*, 2003, vol. 75, 3596-3605 [0141]
- **TYANOVA, S. ; TEMU, T. ; COX, J.** The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.*, 2016, vol. 11, 2301-2319 [0141]
- **VOLPE, P. ; EREMENKO-VOLPE, T.** Quantitative studies on cell proteins in suspension cultures. *Eur. J. Biochem.*, 1970, vol. 12, 195-200 [0141]
- **ZEILER, M. ; STRAUBE, W. L. ; LUNDBERG, E. ; UHLEN, M. ; MANN, M.** A Protein Epitope Signature Tag (PrEST) library allows SILAC-based absolute quantification and multiplexed determination of protein copy numbers in cell lines. *Mol. Cell. Proteomics*, 2012, vol. 11 [0141]
- **CLAIR, G. et al.** Spatially-resolved proteomics: rapid quantitative analysis of laser capture microdissected alveolar tissue samples. *Sci. Rep.*, 2016, vol. 6, 39223 [0141]
- **PISANIA, A. et al.** Quantitative analysis of cell composition and purity of human pancreatic islet preparations. *Lab. Investig.*, 2010, vol. 90, 1661-1675 [0141]
- **RODRIGUEZ-CALVO, T. et al.** Heterogeneity and lobularity of pancreatic pathology in type 1 diabetes during the prediabetic phase. *J. Histochem. Cytochem.*, 2015, vol. 63, 626-636 [0141]
- **RICHARDSON, S. J. et al.** Islet cell hyperexpression of HLA class I antigens : a defining feature in type 1 diabetes. *Diabetologia*, 2016, vol. 59, 2448-2458 [0141]
- **ROWE, P. A. ; CAMPBELL-THOMPSON, M. L. ; SCHATZ, D. A. ; ATKINSON, M. A.** The pancreas in human type 1 diabetes. *Semin. Immunopathol.*, 2011, vol. 33, 29-43 [0141]
- **WHITE, A. K. et al.** High-throughput microfluidic single-cell RT-qPCR. *Proc. Natl. Acad. Sci. U. S. A.*, 2011, vol. 108, 13999-14004 [0141]
- **ZHU, Y. ; FANG, Q.** Integrated droplet analysis system with electrospray ionization-mass spectrometry using a hydrophilic tongue-based droplet extraction interface. *Anal. Chem.*, 2010, vol. 82, 8361-8366 [0141]
- **ZHU, Y. et al.** Printing 2-dimentional droplet array for single-cell reverse transcription quantitative per assay with a microfluidic robot. *Sci. Rep.*, 2015, vol. 5, 9551 [0141]
- **ZHU, Y. et al.** Nanoliter-scale protein crystallization and screening with a microfluidic droplet robot. *Sci. Rep.*, 2014, vol. 4, 5046 [0141]
- **SCHNEIDER, C. A ; RASBAND, W. S. ; ELICEIRI, K. W.** NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods*, 2012, vol. 9, 671-675 [0141]
- **YU, Y. Q. ; GILAR, M. ; LEE, P. J. ; BOUVIER, E. S. P. ; GEBLER, J. C.** Enzyme-friendly, mass spectrometry-compatible surfactant for in-solution enzymatic digestion of proteins. *Anal. Chem.*, 2003, vol. 75, 6023-6028 [0141]
- **TYANOVA, S. et al.** The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods*, 2016, vol. 13, 731-740 [0141]
- **SPITZER, M. ; WILDENHAIN, J. ; RAPPSILBER, J. ; TYERS, M.** BoxPlotR: a web tool for generation of box plots. *Nat. Methods*, 2014, vol. 11, 121-2 [0141]